inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading fasb org gaap deferredincometaxesandotherassetsnoncurrenthttp fasb org gaap otheraccruedliabilitiescurrenthttp www abbott com fasb org gaap deferredincometaxesandotherassetsnoncurrenthttp fasb org gaap otheraccruedliabilitiescurrenthttp www abbott com gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap employeestockoptionmemberabt gaap gaap restrictedstockunitsrsumemberabt gaap gaap maximummemberus gaap restrictedstockawardsmemberabt gaap gaap sellinggeneralandadministrativeexpensesmemberabt gaap researchanddevelopmentexpensememberabt gaap costofsalesmemberabt restructuringplanbusinessacquisitionst judeandalereinc restructuringplanbusinessacquisitionst judeandalereinc gaap sellinggeneralandadministrativeexpensesmemberabt restructuringplanbusinessacquisitionst judeandalereinc gaap researchanddevelopmentexpensememberabt restructuringplanbusinessacquisitionst judeandalereinc gaap costofsalesmemberabt restructuringplanbusinessacquisitionst judeandalereinc restructuringplanbusinessacquisitionst judeandalereinc restructuringplanbusinessacquisitionst judeandalereinc gaap nonusmemberus gaap allothersegmentsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt usus gaap allothersegmentsmemberabt usabt nutritionalproductsmemberabt usabt nutritionalproductsmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap allothersegmentsmemberabt usabt usabt usabt nutritionalproductsmemberabt nutritionalproductsmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt establishedpharmaceuticalproductsmemberabt establishedpharmaceuticalproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt gaap gaap nonusmemberus gaap allothersegmentsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt usus gaap allothersegmentsmemberabt usabt nutritionalproductsmemberabt usabt nutritionalproductsmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap allothersegmentsmemberabt usabt usabt usabt nutritionalproductsmemberabt nutritionalproductsmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt establishedpharmaceuticalproductsmemberabt establishedpharmaceuticalproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt gaap gaap nonusmemberus gaap allothersegmentsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt nutritionalproductsmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt medicaldevicesmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt establishedpharmaceuticalproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt gaap nonusmemberabt diagnosticproductsmemberabt usus gaap allothersegmentsmemberabt usabt nutritionalproductsmemberabt usabt nutritionalproductsmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt medicaldevicesmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt usabt diagnosticproductsmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap nonusmemberabt gaap allothersegmentsmemberabt usabt usabt usabt nutritionalproductsmemberabt nutritionalproductsmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt medicaldevicesmemberabt establishedpharmaceuticalproductsmemberabt establishedpharmaceuticalproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt diagnosticproductsmemberabt gaap otherexitcostsmemberabt otherexitcostsmemberabt restructuringplanbusinessacquisitionst judeandalereinc restructuringplanbusinessacquisitionst judeandalereinc gaap costofsalesmemberabt otherexitcostsmemberabt inventoryrelatedchargesmemberabt fixedassetwritedownsmemberabt inventoryrelatedchargesmemberabt fixedassetwritedownsmemberabt gaap sellinggeneralandadministrativeexpensesmemberabt gaap researchanddevelopmentexpensememberabt gaap costofsalesmemberabt cepheavalvetechnologiesinc gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap foreignexchangeforwardmemberus gaap nondesignatedmemberus gaap gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap foreignexchangeforwardmemberus gaap nondesignatedmemberus gaap gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap foreignexchangeforwardmemberus gaap nondesignatedmemberus gaap minimummemberus gaap minimummemberus gaap maximummemberus gaap maximummemberus gaap abbottirelandfinancingdacmemberus gaap otherexitcostsmemberabt gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap debtmemberus gaap netinvestmenthedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap debtmemberus gaap netinvestmenthedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap debtmemberus gaap netinvestmenthedgingmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberabt maximummemberabt gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap gaap gaap minimummemberus gaap minimummemberus gaap minimummemberabt maximummemberus gaap maximummemberus gaap maximummemberabt gaap gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap longtermdebtmemberus gaap debtmemberus gaap netinvestmenthedgingmemberus gaap gaap accruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap accruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap longtermdebtmemberus gaap debtmemberus gaap netinvestmenthedgingmemberus gaap gaap accruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap accruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap deferredincometaxesandotherassetsmemberus gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap otherprepaidexpensesandreceivablesmemberus gaap foreignexchangeforwardmemberus gaap otherprepaidexpensesandreceivablesmemberus gaap foreignexchangeforwardmemberus gaap gaap gaap deferredincometaxesandotherassetsmemberus gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap otherprepaidexpensesandreceivablesmemberus gaap foreignexchangeforwardmemberus gaap otherprepaidexpensesandreceivablesmemberus gaap foreignexchangeforwardmemberus gaap gaap gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap gaap gaap ustreasuryandgovernmentmemberus gaap gaap ustreasuryandgovernmentmemberus gaap gaap ustreasuryandgovernmentmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap uslargecapitalequitysecuritiesmemberus gaap uslargecapitalequitysecuritiesmemberus gaap foreignequitysecuritiesmemberus gaap foreignequitysecuritiesmemberus gaap definedbenefitplanotherassetsmemberus gaap definedbenefitplanotherassetsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap ustreasuryandgovernmentmemberus gaap gaap ustreasuryandgovernmentmemberus gaap gaap ustreasuryandgovernmentmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap otherdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fixedincomefundsmemberus gaap gaap fixedincomefundsmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap usmidandsmallcapitalequitysecuritiesmemberus gaap uslargecapitalequitysecuritiesmemberus gaap uslargecapitalequitysecuritiesmemberus gaap foreignequitysecuritiesmemberus gaap foreignequitysecuritiesmemberus gaap definedbenefitplanotherassetsmemberus gaap definedbenefitplanotherassetsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap abbottirelandfinancingdacmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap stjudemedicalinc memberus gaap stjudemedicalinc memberus gaap minimummemberabt minimummemberabt maximummemberabt maximummemberabt cepheavalvetechnologiesinc gaap gaap gaap gaap gaap gaap gaap gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap operatingsegmentsmemberabt gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap materialreconcilingitemsmemberus gaap gaap gaap materialreconcilingitemsmemberus gaap gaap gaap gaap gaap gaap gaap foreignexchangeforwardmemberus gaap cashflowhedgingmemberus gaap gaap gaap gaap gaap gaap gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap abbottirelandfinancingdacmemberabt abbottirelandfinancingdacmemberabt gaap gaap gaap gaap gaap gaap usdxbrli purexbrli usdxbrli eurabt jpy united statessecurities and exchange commissionwashington mark one annual report pursuant to section or of the security exchange act of transition report pursuant to section or of the security exchange act of for the fiscal year ended december file number abbott laboratory an illinois abbott park roadabbott park illinois employer identification number telephone number security registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon share without par valueabtnew york stock exchangechicago stock exchange inc indicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control over financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the act yes no the aggregate market value of the share of voting stock held by nonaffiliates of the registrant computed by reference to the closing price reported on the new york stock exchange of the last business day of abbott laboratory recently completed second fiscal quarter june wa abbott ha no non voting common equity number of common share outstanding of january incorporated by referenceportions of the abbott laboratory proxy statement are incorporated by reference into part iii the proxy statement will be filed on or about march part iitem businessgeneral development of businessabbott laboratory is an illinois corporation incorporated in abbott principal business is the discovery development manufacture and sale of broad and diversified line of health care product narrative description of businessabbott ha four reportable segment established pharmaceutical product diagnostic product nutritional product and medical device established pharmaceutical productsthese product include broad line of branded generic pharmaceutical manufactured worldwide and marketed and sold outside the united state in emerging market these product are generally sold directly to wholesaler distributor government agency health care facility pharmacy and independent retailer from abbott owned distribution center and public warehouse depending on the market served certain product are co marketed or co promoted with or licensed from other company the principal product included in the broad therapeutic area portfolio of the established pharmaceutical product segment are gastroenterology product including creon for the treatment of pancreatic exocrine insufficiency associated with several underlying condition including cystic fibrosis and chronic pancreatitis duspatal and dicetel for the treatment of irritable bowel syndrome or biliary spasm heptral transmetil and samyr for the treatment of intrahepatic cholestasis associated with liver disease or depressive symptom and duphalac for regulation of the physiological rhythm of the colon woman health product including duphaston for the treatment of many different gynecological disorder and femoston hormone replacement therapy for postmenopausal woman cardiovascular and metabolic product including lipanthyl and tricor for the treatment of dyslipidemia teveten and teveten plus for the treatment of essential hypertension and physiotens for the treatment of hypertension and synthroid for the treatment of hypothyroidism pain and central nervous system product including serc for the treatment of ménière disease and vestibular vertigo brufen for the treatment of pain fever and inflammation and sevedol for the treatment of severe migraine and respiratory drug and vaccine including the anti infective clarithromycin sold under the trademark biaxin klacid and klaricid and influvac an influenza vaccine the established pharmaceutical product segment directs it primary marketing effort toward building strong brand with key stakeholder including consumer pharmacist physician and other healthcare provider government agency are also important customer competition in the established pharmaceutical product segment is generally from other health care and pharmaceutical company in addition the substitution of generic drug for the brand prescribed and introduction of additional form of already marketed established product by generic or branded competitor may increase competitive pressure used throughout the text of this report on form the term abbott refers to abbott laboratory an illinois corporation or abbott laboratory and it consolidated subsidiary the context requires diagnostic productsthese product include broad line of diagnostic system and test manufactured marketed and sold worldwide these product are generally marketed and sold directly to blood bank hospital commercial laboratory clinic physician office retailer government agency alternate care testing site and plasma protein therapeutic company from abbott owned distribution center public warehouse or third party distributor the principal product included in the diagnostic product segment are core laboratory system in the area of immunoassay clinical chemistry hematology and transfusion medicine including the alinity family of instrument architect abbott prism and cell dyn with assay used for screening and or diagnosis for cancer cardiac metabolics drug of abuse fertility general chemistry infectious disease such hepatitis and hiv therapeutic drug monitoring and suite of sars cov serology assay molecular diagnostics polymerase chain reaction pcr instrument system including alinity and that automate the extraction purification and preparation of dna and rna from patient sample and detect and measure infectious agent including hiv hepatitis hpv sexually transmitted infection sars cov and influenza and respiratory syncytial virus rsv and product for oncology with the vysis fish product line of genomic based test point of care system including the stat and next generation stat alinity and cartridge for testing blood gas chemistry electrolyte coagulation and immunoassay rapid diagnostics lateral flow testing product in the area of infectious disease such sars cov including the binaxnow and panbio rapid testing platform influenza hiv hepatitis and tropical disease such malaria and dengue fever molecular point of care testing for hiv including the pima hiv viral load test and for sars cov and influenza rsv and strep including the id rapid molecular system cardiometabolic testing including afinion and cholestech ldx platform and test toxicology business for drug and alcohol testing and remote patient monitoring and consumer self testing and informatics and automation solution for use in laboratory including laboratory automation system such the glp track system the rals point of care solution and aliniq suite of informatics tool and professional service the diagnostic product segment product are subject to competition in technological innovation price convenience of use service instrument warranty provision product performance laboratory efficiency long term supply contract and product potential for overall cost effectiveness and productivity gain product in this segment can be subject to rapid product obsolescence or regulatory change although abbott ha benefited from technological advantage of certain of it current product these advantage may be reduced or eliminated competitor introduce new product nutritional productsthese product include broad line of pediatric and adult nutritional product manufactured marketed and sold worldwide these product are generally marketed and sold directly to consumer and to institution wholesaler retailer health care facility government agency and third party distributor from abbott owned distribution center or third party distributor the principal product included in the nutritional product segment are various form of infant formula and follow on formula including similac similac total care similac pro advance similac advance similac advance non gmo similac pro sensitive similac sensitive similac sensitive non gmo go grow by similac similac neosure similac organic similac special care similac total comfort similac for supplementation isomil advance isomil alimentum gain grow similac en mei li and eleva adult and other pediatric nutritional product including ensure ensure plus ensure enlive ensure with nutrivigor ensure max protein ensure high protein glucerna glucerna hunger smart prosure pediasure pediasure sidekick pediasure peptide elecare juven abound pedialyte and zone perfect and nutritional product used in enteral feeding in health care institution including jevity glucerna cal glucerna cal osmolite oxepa freego enteral pump and freego set nepro and vital primary marketing effort for nutritional product are directed toward consumer or to securing the recommendation of abbott brand of product by physician or other health care professional in addition nutritional product are also promoted directly to the public by consumer marketing effort in market permitted competition for nutritional product in the segment is generally from other diversified consumer and health care manufacturer competitive factor include consumer advertising formulation packaging scientific innovation price retail distribution and availability of product form significant aspect of competition is the search for ingredient innovation the introduction of new product by competitor change in medical practice and procedure and regulatory change can result in product obsolescence in addition private label and local manufacturer product may increase competitive pressure medical devicesthese product include broad line of rhythm management electrophysiology heart failure vascular and structural heart device for the treatment of cardiovascular disease and diabetes care product for people with diabetes well neuromodulation device for the management of chronic pain and movement disorder medical device are manufactured marketed and sold worldwide in the united state depending upon the product medical device are generally marketed and sold directly to wholesaler hospital ambulatory surgery center physician office and distributor from abbott owned distribution center and public warehouse outside the united state sale are made either directly to customer or through distributor depending on the market served the principal product included in the medical device segment are rhythm management product including assurity mri and endurity mri pacemaker system ellipse fortify assura and gallant implantable cardioverter defibrillator and gallant and quadra assura mp implantable cardioverter defibrillator with cardiac resynchronization therapy and multipoint pacing technology and confirm rx and jot dx implantable cardiac monitor electrophysiology product including the tacticath family of ablation catheter and flexability irrigated ablation catheter ampere rf ablation generator ensite family of cardiac mapping system agilis nxt steerable introducer the advisor hd grid mapping catheter viewflex family of intracardiac echocardiography catheter and viewmate ultrasound system heart failure related product including the heartmate left ventricular device family the cardiomems hf system pulmonary artery sensor heart failure monitoring system and the centrimag system an acute circulatory support system vascular product including the xience family of drug eluting coronary stent system developed on the multi link vision platform starclose se perclose proglide and perclose prostyle vessel closure device trek coronary balloon dilatation product hi torque balance middleweight universal ii guidewires supera peripheral stent system peripheral vascular stent system acculink accunet and xact emboshield carotid stent system the optis integrated system with ultreon software compatible with the dragonfly optis imaging catheter and pressurewire fractional flow reserve measurement system and the jeti peripheral thrombectomy system for clot removal structural heart product including mitraclip transcatheter mitral valve repair system trifecta valve with glide technology surgical tissue heart valve portico and navitor transcatheter aortic heart valve regent mechanical heart valve amplatzer pfo occluders amplatzer amulet occluder device the tendyne transcatheter mitral valve implantation tmvi system and the triclip transcatheter tricuspid valve repair system continuous glucose and blood glucose monitoring system including test strip sensor data management decision software and accessory for people with diabetes under the freestyle brand such the freestyle libre system and neuromodulation product including spinal cord stimulators proclaim elite and proclaim xr recharge free implantable pulse generator ipg and prodigy mri ipg each with burstdr stimulation and proclaim drg ipg neurostimulation device designed for dorsal root ganglion therapy for the treatment of chronic pain disorder and the infinity deep brain stimulation system with directional lead technology for the treatment of movement disorder these product are subject to competition in technological innovation price convenience of use service product performance long term supply contract and product potential for overall cost effectiveness and productivity gain some product in this segment can be subject to rapid product obsolescence or regulatory change although abbott ha benefited from technological advantage of certain of it current product these advantage may be reduced or eliminated competitor introduce new product information with respect to abbott business in generalsources and availability of raw materialsabbott purchase in the ordinary course of business raw material and supply essential to abbott operation from numerous supplier in the united state and around the world due to disruption to the global supply chain caused in part by the covid pandemic abbott ha experienced availability issue with some material and electronic component to date abbott ha been able to manage these challenge without significant supply disruption or shortage for raw material and supply more detailed discussion on the covid pandemic disruption of the global supply chain and it resulting impact on abbott business is contained in abbott is subject to risk related to public health crisis such widespread outbreak of infectious disease like the covid pandemic in economic and industry risk under item risk factor patent trademark and licensesabbott is aware of the desirability for patent and trademark protection for it product accordingly where possible patent and trademark are sought and obtained for abbott product in the united state and country of interest to abbott abbott owns or ha license under substantial number of patent and patent application principal trademark and the product they cover are discussed in the narrative description of business on page through these and various patent which expire during the period to in the aggregate are believed to be of material importance in the operation of abbott business abbott belief that no single patent license or trademark is material in relation to abbott business whole seasonal aspect customer and renegotiationthere are no significant seasonal aspect to abbott business abbott ha no single customer that if the customer lost would have material adverse effect on abbott no material portion of abbott business is subject to renegotiation of profit or termination of contract at the election of government environmental mattersabbott belief that it operation comply in all material respect with applicable law and regulation concerning environmental protection regulation under federal state and various other country environmental law impose stringent limitation on emission and discharge to the environment from various manufacturing operation abbott capital and operating expenditure for pollution control in were not material and are not expected to be material in abbott ha been identified one of many potentially responsible party in investigation and or remediation at several location in the united state including puerto rico under the comprehensive environmental response compensation and liability act commonly known superfund abbott is also engaged in remediation at several other site some of which are owned by abbott in cooperation with the environmental protection agency or similar agency it is not feasible to predict with certainty the final cost related to those investigation and remediation activity abbott belief that such cost together with other expenditure to maintain compliance with applicable law and regulation concerning environmental protection not have material adverse effect on abbott financial position cash flow or result of operation human capitalthe sustainability of abbott business depends on attracting engaging and developing talented people with diverse background share abbott mission to help people live healthiest possible life abbott provides it employee opportunity to grow and develop their career market competitive compensation and benefit program and the satisfaction of part of global company dedicated to improving health in more country of december abbott employed approximately people of were employed outside of the woman represented of abbott workforce of it global workforce and of it manager health and safetythe health safety and wellness of it employee is an abbott priority embedded at every level of it business abbott integrated environmental health and safety organization governs health safety and wellness at abbott facility abbott also maintains global policy and standard for managing employee health and safety abbott take holistic approach to employee well being abbott global wellness program are designed to meet the unique need of employee across business and geography and offer wide range of program including supporting the mental financial and physical health of employee and their family for example for over year abbott ha annually offered exercise across abbott which is four week physical wellness program that encourages employee to team with colleague and track many minute they exercise each day over abbott employee across country took part in during the covid pandemic abbott ha taken aggressive step to limit exposure and enhance the safety of facility for it employee including providing and requiring the use of personal protective equipment and at many facility providing vaccination providing and requiring onsite covid testing and implementing social distancing in some location employee also have received free over the counter covid test for at home use talent managementabbott ha an integrated global talent management process that is designed to identify and ass talent across the organization and provide equal and consistent opportunity for employee to develop their skill all level of employee participate in abbott annual performance management process to create development plan that support their particular career objective and abbott provides broad range of training mentoring and other development opportunity to help it employee meet these objective the board of director conduct an annual talent management review focusing on development of talent diversity and succession planning for critical position similar review take place at every level of abbott to develop talent and diversity across the organization diversity and inclusion abbott is committed to developing workplace that is inclusive for all abbott tie executive compensation to human capital management including diversity outcome to sustain an inclusive culture and the fair and balanced treatment of abbott employee in abbott issued it first ever diversity equity and inclusion report which describes abbott plan strategy and action to fulfill it commitment to develop an inclusive workplace abbott employee network play an important role in building an inclusive culture across all abbott operation member of abbott senior management serf sponsor for each of these network helping to align their objective with abbott business strategy abbott ha ten such network which are advancing professional network supporting early career employee asian leadership and cultural network black business network flex network supporting employee with part time and flexible schedule la voice network supporting hispanic and latino employee disability network supporting people with disability pride supporting lgbtq employee veteran network woman leader of abbott and woman in stem all abbott employee are encouraged to join any of the employee network abbott offer professional development program which provide recent college graduate the opportunity to rotate through different area of abbott often with the chance to work outside their home country in of the participant were woman also abbott host hundred of college student for paid internship in of the intern were woman and were minority further abbott ha offered stem internship program for high school student in the since and beginning in student who complete the program are eligible to receive college credit for their experience the program objective is to increase the number of student pursuing stem related career and contribute to more diverse talent pipeline for abbott in of the stem intern were woman and were minority compensation and benefitsabbott is committed to building retaining and motivating diverse talent pipeline that can meet the current and future need of it business to that end abbott provides market competitive compensation healthcare benefit continuing education benefit pension and or retirement saving plan financial support for employee with student loan debt and several program to facilitate employee building an ownership stake in abbott including global long term incentive program for employee generally beginning at the manager level abbott also ha procedure and process focused on ensuring employee receive equitable compensation regardless of race or gender or other personal characteristic regulationthe development manufacture marketing sale promotion and distribution of abbott product are subject to comprehensive government regulation by the food and drug administration fda and similar international regulatory agency government regulation by various international supranational federal and state agency address among other matter the development and approval to market abbott product well the inspection of and control over research and laboratory procedure clinical investigation product approval and manufacturing labeling packaging supply chain marketing and promotion pricing and reimbursement sampling distribution quality control post market surveillance record keeping storage and disposal practice in addition abbott clinical laboratory and associated testing service are subject to comprehensive government regulation including registration certification and licensure by federal state and local agency such the center for medicare medicaid service the drug enforcement administration the substance abuse and mental health service administration and their respective foreign counterpart certain of these agency require clinical laboratory to meet quality assurance quality control and personnel standard and undergo inspection during the covid public health emergency many pandemic related product including diagnostic test were authorized by regulator for emergency use solely during the pandemic in addition many government enacted policy to expedite or promote access to health care in order to slow or stop the spread of the virus example include expansion of telehealth coverage and increased reimbursement for diagnostic testing it is uncertain when the public health emergency will end and to extent these policy will continue or revert back to previous policy abbott international operation are also affected by trade and investment regulation in many country these may require local investment restrict abbott investment or limit the import of raw material and finished product abbott laboratory facility home monitoring service and durable medical equipment supplier which provide service related product and medical device to consumer are subject to additional law and regulation applicable to health care provider and supplier that submit claim for reimbursement to third party payors in the united state medicare medicaid and other third party payors may from time to time conduct inquiry claim audit investigation and enforcement action relating to the claim or enrollment criterion abbott is subject to law and regulation pertaining to health care fraud and abuse including state and federal anti kickback anti self referral and false claim law in the united state prescription drug nutrition and medical device manufacturer such abbott are also subject to tax well application product user establishment and other fee governmental agency can also invalidate intellectual property right compliance with these law and regulation is costly and materially affect abbott business among other effect health care regulation and significant change thereto such the introduction of the medical device regulation and the in vitro diagnostic medical device regulation in the european union substantially increase the time difficulty and cost incurred in developing obtaining and maintaining approval to market and marketing newly developed and existing product abbott expects this regulatory environment will continue to require significant technical expertise and investment to ensure compliance failure to comply can delay the release of new product or result in regulatory and enforcement action the seizure or recall of product the suspension or revocation of the authority necessary for product production and sale suspension or revocation of billing privilege and other civil or criminal sanction including fine and penalty similarly compliance with the law and regulation governing clinical laboratory and testing service requires specialized expertise failure to comply with these regulatory requirement can result in sanction including suspension revocation or limitation of laboratory certification which is necessary to conduct business well significant fine or criminal penalty abbott business can also be affected by ongoing study of the utilization safety efficacy and outcome of health care product and their component that are regularly conducted by industry participant government agency and others these study can call into question the utilization safety and efficacy of previously marketed product in some case these study have resulted and may in the future result in the discontinuation of marketing of such product in one or more country and may give rise to claim for damage from person who believe they have been injured result of their use access to human health care product continues to be subject of investigation and action by governmental agency legislative body and private organization in many country major focus is cost containment effort to reduce health care cost are also being made in the private sector notably by health care payors and provider which have instituted various cost reduction and containment measure abbott expects insurer and provider will continue attempt to reduce the cost or utilization of health care product many country control the price of health care product directly or indirectly through reimbursement payment pricing or coverage limitation budgetary pressure on health care payors may also heighten the scope and severity of pricing pressure on abbott product for the foreseeable future in the united state the federal government regularly evaluates reimbursement for medical device diagnostics supply and other product well the procedure in which these product may be used the government follows diagnosis related group drg payment system for certain institutional service provided under medicare or medicaid and ha implemented prospective payment system pps for service delivered in hospital outpatient nursing home and home health setting drg and pps entitle health care facility to fixed reimbursement based on the diagnosis and or procedure rather than actual cost incurred in patient treatment thereby increasing the incentive for the facility to limit or control expenditure for many health care product other payment methodology change have been proposed and implemented from time to time for example medicare implemented competitive bidding system for certain durable medical equipment including diabetes product enteral nutrition product and supply additionally the protecting access to medicare act established new payment system for clinical laboratory test in the patient protection and affordable care act the affordable care act includes provision known the physician payment sunshine act which requires manufacturer of drug device and medical supply covered under medicare and medicaid to record any transfer of value to physician and teaching hospital and to report this data to the center for medicare medicaid service for subsequent public disclosure in october the substance use disorder prevention that promotes opioid recovery and treatment for patient and community act significantly expanded the type of healthcare provider for which reporting is required beginning with report filed in similar reporting requirement have also been enacted on the state level domestically and an increasing number of government worldwide either have adopted or are considering similar law requiring transparency of interaction with health care professional failure to report appropriate data may result in civil or criminal fine and or penalty policy change or implementation of new health care legislation could result in significant change to health care system in the united state this could include potential modification including expansion or repeal of all or part of the affordable care act the regulation of data privacy and security and the protection of the confidentiality of certain personal information including patient health information financial information and other sensitive personal information is increasing for example the european union china various other country and various state california virginia and colorado have enacted data protection law that contain significant compliance obligation and financial penalty for noncompliance in addition regulator with general consumer protection authority such the federal trade commission and state attorney general are focused on how consumer data is used by entity in the health care industry further there are regulation of data privacy and security that are specific to health care company for example the department of health and human service ha issued rule governing the use disclosure and security of protected health information and the fda ha issued further guidance concerning cybersecurity for medical device in addition certain country have issued or are considering data localization law which limit company ability to transfer protected data across country border failure to comply with data privacy and security law and regulation can result in business disruption and enforcement action which could include civil or criminal penalty transferring and managing protected information will become more challenging law and regulation are enacted or amended and abbott expects there will be increasing complexity in this area governmental cost containment effort also affect abbott nutritional product business in the united state for example under regulation governing the federally funded special supplemental nutrition program for woman infant and child all state must have cost containment program for infant formula result through competitive bidding state obtain rebate from manufacturer of infant formula whose product are used in the program abbott expects debate to continue at all government level worldwide over the manufacture quality assurance requirement marketing authorization process post market surveillance requirement availability method of delivery and payment for health care product and service well data privacy and security abbott belief that future legislation and regulation in the market it serf could affect the timing and expense associated with bringing health care product or service to market access to health care product and service increase rebate reduce price or reimbursement or the rate of price increase for health care product and service change health care delivery system create new fee and obligation for the pharmaceutical nutrition diagnostic and medical device industry or require additional reporting and disclosure it is not possible to predict the extent to which abbott or the health care industry in general might be affected by the matter discussed internet informationcopies of abbott annual report on form quarterly report on form current report on form and amendment to those report filed or furnished pursuant to section or of the security exchange act of are available free of charge through abbott investor relation website www abbottinvestor com soon reasonably practicable abbott electronically file the material with or furnishes it to the security and exchange commission the commission these report and other information are also available free of charge at www sec gov abbott corporate governance guideline outline of directorship qualification code of business conduct and the charter of abbott audit committee compensation committee nomination and governance committee and public policy committee are all available on abbott investor relation website www abbottinvestor com item risk factorsin addition to the other information in this report the following risk factor should be considered deciding to invest in any of abbott security additional risk and uncertainty not presently known to abbott or risk abbott currently considers immaterial could also affect abbott actual result abbott business financial condition result of operation or prospect could be materially adversely affected by any of these risk business and operational risksabbott may acquire other business license right to technology or product form alliance or dispose of or spin off business which could cause it to incur significant expense and could negatively affect profitability abbott may pursue acquisition licensing arrangement and strategic alliance or dispose of or spin off some of it business part of it business strategy abbott may not complete these transaction in timely manner on cost effective basis or at all and may not realize the expected benefit if abbott is successful in making an acquisition the product and technology that are acquired may not be successful or may require significantly greater resource and investment than originally anticipated abbott may not be able to integrate acquisition successfully into it existing business or transition disposed business efficiently and could incur or assume significant debt and unknown or contingent liability abbott could also experience negative effect on it reported result of operation from acquisition or disposition related charge amortization of expense related to intangible and charge for impairment of long term asset these effect could cause deterioration of abbott credit rating result in increased borrowing cost and interest expense and decrease liquidity abbott depends on sophisticated information technology system and maintains protected personal data and cyber attack or other breach affecting these information technology system or protected data could have material adverse effect on abbott result of operation similar to other large multi national company the size and complexity of the information technology system on which abbott relies for both it infrastructure and product make them susceptible to cyber attack malicious intrusion breakdown destruction loss of data privacy or other significant disruption these system have been and are expected to continue to be the target of malware and other cyber attack in addition third party hacking attempt may cause abbott information technology system and related product protected data or proprietary information to be compromised or stolen significant attack or other disruption could result in adverse consequence including increased cost and expense manufacturing challenge or disruption problem with product functionality damage to customer relation reputational damage lost revenue and legal or regulatory penalty abbott also collect manages and process protected personal data including protected health information in connection with certain medical product and service offering abbott is subject to certain regional and local data protection law that prohibit or restrict the transfer of protected data across country border for additional information concerning data privacy and security regulation see the discussion in regulation under item business breach of protected personal information could result in adverse consequence including regulatory inquiry or litigation increased cost and expense reputational damage lost revenue and fine or penalty abbott invests in it system and technology and in the protection of it product and data to reduce the risk of an attack or other significant disruption and monitor it system on an ongoing basis for any current or potential threat or vulnerability and for change in technology and the regulatory environment there can be no assurance that these measure and effort will prevent future attack or other significant disruption to any of the system on which abbott relies or that related product issue will not arise in the future similarly there can be no assurance that third party information technology provider with whom abbott contract will not suffer significant attack or disruption that impact customer like abbott any significant breach attack or other disruption involving abbott system or product could have material adverse effect on abbott business abbott research and development effort may not succeed in developing commercially successful product and technology which may cause abbott revenue and profitability to decline to remain competitive abbott must continue to launch new product and technology to accomplish this abbott commits substantial effort fund and other resource to research and development risk of failure is inherent in the research and development of new product and technology abbott must make ongoing substantial expenditure without any assurance that it effort will be commercially successful failure can occur at any point in the process including after significant fund have been invested promising new product and technology may fail to reach the market or may only have limited commercial success of efficacy or safety concern failure to achieve positive clinical outcome inability to obtain necessary regulatory approval limited scope of approved us excessive cost to manufacture failure to establish or maintain intellectual property right or infringement of the intellectual property right of others even if abbott successfully develops new product or enhancement or new generation of abbott existing product they may be quickly rendered obsolete by changing customer preference changing industry or regulatory standard or competitor innovation innovation may not be accepted quickly in the marketplace because of among other thing entrenched pattern of clinical practice or uncertainty over third party reimbursement abbott can not state with certainty when or whether any of it product under development will be launched whether it will be able to develop license or otherwise acquire compound or product or whether any product will be commercially successful failure to launch successful new product or technology or new indication or us for existing product may cause abbott product or technology to become obsolete causing abbott revenue and operating result to suffer the manufacture of many of abbott product is highly exacting and complex process and if abbott or one of it supplier encounter problem manufacturing product abbott business could suffer the manufacture of many of abbott product is highly exacting and complex process due in part to strict regulatory requirement problem may arise during manufacturing for variety of reason including equipment malfunction failure to follow specific protocol and procedure problem with raw material or the global supply chain cyber attack natural disaster and environmental factor in addition single supplier are currently used for certain product and material if problem arise during the production of lot or batch of product those product may have to be discarded if problem are not discovered before the product is released to the market recall and product liability cost may also be incurred any of these event could among other thing lead to increased cost lost revenue damage to customer relation time and expense spent investigating the cause and depending on the cause similar loss with respect to other lot batch or product to the extent abbott or one of it supplier experience significant manufacturing problem this could have material adverse effect on abbott revenue and profitability abbott ha significant indebtedness which could adversely affect it business including decreasing it business flexibility of december abbott consolidated indebtedness wa approximately billion this consolidated indebtedness could have the effect among other thing of reducing abbott flexibility to respond to changing business and economic condition and reducing fund available for working capital capital expenditure acquisition and other general corporate purpose further abbott may be required to raise additional financing for working capital capital expenditure future acquisition or other general corporate purpose abbott ability to arrange additional financing or refinancing will depend on among other factor abbott financial position and performance well prevailing market condition and other factor beyond abbott control consequently abbott can not assure that it will be able to obtain additional financing or refinancing on term acceptable to abbott or at all which could adversely impact abbott ability to make scheduled payment with respect to it consolidated indebtedness and it profitability and financial condition additionally further borrowing could cause deterioration of abbott credit rating abbott credit rating reflect each credit rating agency opinion of abbott financial strength operating performance and ability to meet it debt obligation adverse change in abbott credit rating may result in increased borrowing cost for future long term debt or short term borrowing facility and may limit financing option including access to the unsecured borrowing market abbott may also be subject to additional restrictive covenant that would reduce flexibility legal and regulatory risksabbott is subject to numerous governmental regulation and it can be costly to comply with these regulation and to develop compliant product and process abbott product are subject to rigorous regulation by the fda and numerous international supranational federal and state authority the process of obtaining regulatory approval to market drug medical device diagnostic product or nutritional product can be costly and time consuming and approval might not be granted for future product or additional indication or us of existing product on timely basis if at all delay in the receipt of or failure to obtain approval for future product or new indication and us could result in delayed realization of product revenue reduction in revenue and substantial additional cost in addition no assurance can be given that abbott will remain in compliance with applicable fda and other regulatory requirement once approval or marketing authorization ha been obtained for product these requirement include among other thing regulation regarding manufacturing practice product labeling and advertising and postmarketing reporting including adverse event report and field alert many of abbott facility and procedure and those of abbott supplier are subject to ongoing regulation including periodic inspection by the fda and other regulatory authority abbott must incur expense and spend time and effort to ensure compliance with these complex regulation possible regulatory action for non compliance could include warning letter fine damage injunction civil penalty recall seizure of abbott product and criminal prosecution these action could result in among other thing substantial modification to abbott business practice and operation refund recall or seizure of abbott product total or partial shutdown of production in one or more facility while abbott or abbott supplier remedy the alleged violation the inability to obtain future pre market approval or marketing authorization and withdrawal or suspension of current product from the market any of these event could disrupt abbott business and have material adverse effect on abbott revenue profitability and financial condition law and regulation affecting government benefit program could impose new obligation on abbott require abbott to change it business practice and restrict it operation in the future abbott industry is subject to various international supranational federal and state law and regulation pertaining to government benefit program reimbursement price reporting and regulation and health care fraud and abuse including anti kickback and false claim law and international and individual state law relating to pricing and sale and marketing practice violation of these law may be punishable by criminal and or civil sanction including in some instance substantial fine imprisonment and exclusion from participation in government health care program including medicare medicaid and veteran administration health program in the these law and regulation are broad in scope and they are subject to evolving interpretation which could require abbott to incur substantial cost associated with compliance or to alter one or more of it sale or marketing practice in addition violation of these law or allegation of such violation could disrupt abbott business and result in material adverse effect on abbott revenue profitability and financial condition change in the health care regulatory environment may adversely affect abbott business both in the and internationally government authority may enact change in regulatory requirement make legislative or administrative reform to existing reimbursement program make adverse decision relating to abbott product coverage or reimbursement or make change to patient access to health care all of which could adversely impact the demand for and usage of abbott product or the price that abbott customer are willing to pay for them further in the number of the provision of the affordable care act and the health care and education reconciliation act of address access to health care product and service these provision may be modified expanded repealed or otherwise invalidated in whole or in part future rulemaking could affect rebate price or the rate of price increase for health care product and service or required reporting and disclosure abbott can not predict the timing or impact of any future rulemaking or change in the law for additional information concerning health care regulation see the discussion in regulation under item business the expiration or loss of intellectual property protection and license may affect abbott future revenue and operating income many of abbott business rely on patent and trademark and other intellectual property protection although most of the challenge to abbott intellectual property have come from other company government may also challenge intellectual property protection to the extent abbott intellectual property is successfully challenged invalidated or circumvented or to the extent it doe not allow abbott to compete effectively abbott business could suffer to the extent that country not enforce abbott intellectual property right abbott future revenue and operating income could be reduced any material litigation regarding abbott patent and trademark is described in the section captioned legal proceeding significant safety concern could arise for abbott product which could have material adverse effect on abbott revenue and financial condition health care product typically receive regulatory approval based on data obtained in controlled clinical trial of limited duration following regulatory approval these product will be used over longer period of time in many patient investigator may also conduct additional and perhaps more extensive study if new safety issue are reported abbott may be required to amend the condition of use for product for example abbott may be required to provide additional warning on product label or narrow it approved intended use either of which could reduce the product market acceptance if serious safety issue arise with an abbott product sale of the product could be halted by abbott or by regulatory authority safety issue affecting supplier or competitor product also may reduce the market acceptance of abbott product in addition in the ordinary course of business abbott is the subject of product liability claim and lawsuit alleging that it product or the product of other company that abbott promotes have resulted or could result in an unsafe condition for or injury to patient product liability claim and lawsuit safety alert or product recall and other allegation of product safety or quality issue regardless of their validity or ultimate outcome may have material adverse effect on abbott business and reputation and on abbott ability to attract and retain customer consequence may also include additional cost decrease in market share for the product lower income or exposure to other claim product liability loss are self insured product liability claim could have material adverse effect on abbott profitability and financial condition economic and industry risksabbott is subject to risk related to public health crisis such widespread outbreak of infectious disease like the covid pandemic global healthcare company public health crisis such the widespread outbreak of infectious disease like the covid pandemic may negatively impact abbott operation health concern and significant change in political or economic condition caused by such outbreak can cause significant reduction in demand for certain product increased difficulty in serving customer disrupt manufacturing and supply chain and negatively affect abbott operation well the operation of it supplier distributor and other third party partner furthermore such widespread outbreak may impact the broader economy of affected country including negatively impacting economic growth the proper functioning of financial and capital market foreign currency exchange rate and interest rate to date the covid pandemic ha affected abbott diversified health care business in various way with some business performing at the level required to successfully meet new demand other faced challenge during period when the number of covid case significantly increased and still others being relatively le impacted by the pandemic with regard to covid diagnostic testing the fda issued emergency use authorization euas for several covid related product in and including abbott diagnostic test euas are authorized for the duration of the covid public health emergency unless sooner terminated or revoked abbott is actively pursuing the fda customary regulatory approval process for various covid diagnostic test which ha uncertainty discussed in abbott is subject to numerous governmental regulation and it can be costly to comply with these regulation and to develop compliant product and process in legal and regulatory risk under item risk factor further the demand for covid test ha been and abbott expects it to continue to be highly volatile primarily driven by the emergence and severity of new variant which are unpredictable in addition the covid pandemic ha contributed to global supply chain disruption which ha adversely impacted the cost and availability of certain raw material supply and service while abbott ha taken action to offset some of these inflationary pressure in it supply chain abbott may not be able to completely offset all the increase in it operational cost further abbott ha experienced and may continue to experience availability issue with some service and material used in it product to date abbott ha been able to manage these challenge without significant supply disruption or shortage for service raw material and supply however no assurance can be given that these effort will continue to be successful significant disruption or shortage may result in abbott inability to meet customer demand for certain of it product due to the unpredictability of the duration and impact of the current covid pandemic the extent to which the covid pandemic will have material effect on abbott business financial condition or result of operation is uncertain more detailed discussion on the impact of the covid pandemic on abbott business is contained in the financial review section in item management discussion and analysis of financial condition and result of operation of this report abbott is subject to cost containment effort that could cause reduction in future revenue and operating income in the united state and other country abbott business have experienced downward pressure on product pricing cost containment effort by government and private organization are described in greater detail in the section captioned regulation to the extent these cost containment effort are not offset by greater patient access to health care or other factor abbott future revenue and operating income will be reduced competitor intellectual property may prevent abbott from selling it product or have material adverse effect on abbott future profitability and financial condition in the ordinary course of business abbott is the subject of patent litigation such competitor claim that an abbott product infringes their intellectual property resolving an intellectual property infringement claim can be costly and time consuming and may require abbott to enter into license agreement abbott can not guarantee that it would be able to obtain license agreement on commercially reasonable term successful claim of patent or other intellectual property infringement could subject abbott to significant damage or an injunction preventing the manufacture sale or use of affected abbott product any of these event could have material adverse effect on abbott profitability and financial condition new product and technological advance by abbott competitor may negatively affect abbott result of operation abbott product face intense competition from competitive product competitor product may be safer more effective more effectively marketed or sold or have lower price or superior performance feature than abbott product abbott can not predict with certainty the timing or impact of the introduction of competitor product fluctuation in foreign currency exchange rate may adversely affect abbott financial statement and it ability to realize projected sale and earnings although abbott financial statement are denominated in dollar significant portion of abbott revenue and cost are realized in other currency sale outside of the united state in made up approximately percent of abbott net sale abbott profitability is affected by movement of the dollar other currency fluctuation in exchange rate the dollar and other currency may also affect the reported value of abbott asset and liability well it cash flow some foreign currency are subject to government exchange control while abbott enters into hedging arrangement to mitigate some of it foreign currency exposure abbott can not predict with any certainty change in foreign currency exchange rate or it ability to mitigate these risk information on the impact of foreign exchange rate on abbott financial result is contained in the financial review result of operation section in item management discussion and analysis of financial condition and result of operation of this report discussion of the step taken to mitigate the impact of foreign exchange is contained in item quantitative and qualitative disclosure about market risk in abbott form information on abbott hedging arrangement is contained in note to the consolidated financial statement in this report deterioration in the economic condition and credit quality of certain country may negatively affect abbott result of operation unfavorable economic condition in certain country may increase the time it take to collect outstanding trade receivables financial instability and fiscal deficit in these country may result in additional austerity measure to reduce cost including health care deterioration in the quality of sovereign debt including credit downgrade could increase abbott collection risk where significant amount of abbott receivables in these country are with governmental health care system or where abbott customer depend on payment by government health care system the international nature of abbott business subject it to additional business risk that may cause it revenue and profitability to decline abbott business is subject to risk associated with managing global supply chain and business internationally sale outside of the united state in made up approximately percent of abbott net sale additional risk associated with abbott international operation include differing local product preference and product requirement trade protection measure including tariff import or export licensing requirement other governmental restriction and change to international trade agreement difficulty in establishing staffing and managing operation differing labor regulation potentially negative consequence from change in or interpretation of tax law political and economic instability including sovereign debt issue restriction on local currency conversion and or cash extraction price control limitation on participation in local enterprise expropriation nationalization and other governmental action inflation recession and fluctuation in interest rate diminished protection of intellectual property and potential penalty or other adverse consequence for violation of anti corruption anti bribery and other similar law and regulation including the foreign corrupt practice act and the bribery act event contemplated by these risk may individually or in the aggregate have material adverse effect on abbott revenue and profitability other factor can have material adverse effect on abbott future profitability and financial condition many other factor can affect abbott profitability and it financial condition including change in or interpretation of law and regulation including change in accounting standard taxation requirement product marketing application standard product labeling standard source and use law and environmental law difference between the fair value measurement of asset and liability and their actual value particularly for pension retiree health care stock compensation intangible goodwill and contingent consideration and for contingent liability such litigation the absence of recorded amount or an amount recorded at the minimum compared to the actual amount change in the rate of inflation including the cost of raw material commodity and supply interest rate market value of abbott equity investment and the performance of investment held by abbott or abbott employee benefit trust change in the creditworthiness of counterparties that transact business with or provide service to abbott or abbott employee benefit trust change in business economic and political condition including war political instability terrorist attack the threat of future terrorist activity and related military action global climate change extreme weather and natural disaster the cost and availability of insurance due to any of the foregoing event labor dispute strike slow down or other form of labor or union activity and pressure from third party interest group change in abbott business unit and investment and change in the relative and absolute contribution of each to earnings and cash flow resulting from evolving business strategy changing product mix change in tax law or tax rate both in the and abroad and opportunity existing now or in the future change in the buying pattern of major distributor retailer wholesaler or other customer resulting from buyer purchasing decision pricing seasonality or other factor or other problem with licensors supplier distributor and business partner and legal difficulty any of which could preclude or delay commercialization of product or adversely affect profitability including claim asserting statutory or regulatory violation and adverse litigation decision cautionary statement regarding forward looking statementsthis form contains forward looking statement that are based on management current expectation estimate and projection word such expects anticipates intends plan belief seek estimate forecast variation of these word and similar expression are intended to identify these forward looking statement certain factor including but not limited to those identified under item risk factor of this form may cause actual result to differ materially from current expectation estimate projection forecast and from past result no assurance can be made that any expectation estimate or projection contained in forward looking statement will be achieved or will not be affected by the factor cited above or other unknown or future event abbott undertakes no obligation to release publicly any revision to forward looking statement the result of subsequent event or development except required by law item unresolved staff commentsnone item propertiesas of december abbott owned or leased property totaling approximately million square foot of which approximately is owned by abbott abbott principal corporate office are located in illinois and are owned by abbott abbott operates manufacturing facility globally abbott facility are deemed suitable and provide adequate productive capacity the manufacturing facility are used by abbott reportable segment follows manufacturingreportable segment sitesmedical device product pharmaceutical product product total abbott research and development facility in the united state are primarily located in california illinois minnesota new jersey and ohio abbott also ha research and development facility in various other country including china colombia india singapore spain and the united kingdom there are no material encumbrance on the property item legal proceedingsabbott is involved in various claim legal proceeding and investigation including of january those described below while it is not feasible to predict the outcome of such pending claim proceeding and investigation with certainty management is of the opinion that their ultimate resolution should not have material adverse effect on abbott financial position cash flow or result of operation abbott is defendant in numerous lawsuit involving certain of it specialty infant formula product administered to preterm infant the lawsuit allege that preterm infant developed necrotizing enterocolitis result of being administered cow milk based preterm infant formula product which resulted in personal injury or death of january there were lawsuit pending in federal and state court in which abbott is party the plaintiff seek various damage including punitive damage in january the judicial panel on multidistrict litigation wa asked to consolidate the federal court case for pretrial purpose in addition on december purported class of canadian preterm infant filed suit in british columbia making similar allegation against abbott these plaintiff seek various damage including punitive damage many of the lawsuit name another infant formula manufacturer co defendant in june and july dexcom inc dexcom initiated patent infringement litigation against abbott over certain of abbott continuous glucose monitoring product including those under the freestyle brand in the district court for the eastern district of texas and in the regional court of mannheim in germany in both jurisdiction dexcom seek injunctive relief and monetary damage in all case abbott asserts that it ha license to each of dexcom asserted patent and that the patent are invalid and not infringed in july abbott sued dexcom for patent infringement over certain of dexcom continuous glucose monitoring product in the district court for the district of delaware the regional court of mannheim and dusseldorf in germany and the high court of justice in the united kingdom abbott seek injunctive relief and monetary damage in december abbott filed breach of contract suit against dexcom in the district court for the district of delaware alleging that dexcom breached the party settlement and license agreement by asserting infringement of patent against abbott that dexcom previously licensed to abbott item mine safety disclosuresnot applicable information about our executive officersexecutive officer of abbott are elected annually by the board of director each executive officer hold office successor ha been duly elected or appointed and qualified or until the officer death resignation or removal vacancy may be filled at any time by the board any executive officer may be removed by the board of director when in it judgment removal would serve the best interest of abbott abbott executive officer their age of february and the date of their first election officer of abbott are listed below the executive officer principal occupation and employment for the past five year and the year of appointment to the earliest reported office are also shown unless otherwise stated employment wa by abbott there are no family relationship between any executive officer or director robert ford to present chairman of the board and chief executive officer and director to president and chief executive officer and director to president and chief operating officer and director since to executive vice president medical device elected corporate officer hubert allen to present executive vice president general counsel and secretary elected corporate officer john capek to present executive vice president venture elected corporate officer lisa earnhardt to present executive vice president medical device to president ceo and director intersect ent medical technology company focused on developing treatment for ear nose and throat condition elected corporate officer robert funck jr to present executive vice president finance and chief financial officer to senior vice president finance and controller to vice president controller elected corporate officer john ginascol to present executive vice president core diagnostics to vice president nutrition supply chain elected corporate officer joseph manning to present executive vice president nutritional product to senior vice president international nutrition to vice president nutrition asia pacific elected corporate officer mary moreland to present executive vice president human resource to divisional vice president compensation benefit and hr elected corporate officer daniel salvadori to present executive vice president and group president established pharmaceutical and nutritional product to executive vice president nutritional product to senior vice president established pharmaceutical latin america elected corporate officer andrea wainer to present executive vice president rapid and molecular diagnostics to vice president molecular diagnostics elected corporate officer gregory ahlberg to present senior vice president core laboratory diagnostics commercial operation to vice president diagnostics commercial operation europe middle east and africa to divisional vice president usa abbott diagnostics division elected corporate officer christopher calamari to present senior vice president nutrition to vice president pediatric nutrition to divisional vice president and general manager pediatric nutrition elected corporate officer michael dale to present senior vice president structural heart to vice president structural heart to divisional vice president and general manager structural heart to president and chief executive officer gi dynamic inc medical device company focused on developing gastrointestinal therapy elected corporate officer sammy karam to present senior vice president established pharmaceutical emerging market to divisional vice president global marketing commercial execution established pharmaceutical elected corporate officer fernando mateus to present senior vice president international nutrition to divisional vice president eurisa abbott international nutrition to chief executive officer exeltis usa inc subsidiary of exeltis woman health company focused on respiratory dermatology and endocrinology elected corporate officer louis morrone to present senior vice president rapid diagnostics to vice president transfusion medicine to divisional vice president and general manager transfusion medicine add elected corporate officer michael pederson to present senior vice president to senior vice president electrophysiology and heart failure to senior vice president cardiac arrhythmia and heart failure to divisional vice president and general manager abbott electrophysiology elected corporate officer julie tyler to present senior vice president abbott vascular april to july divisional vice president commercial adc to divisional vice president global marketing avd to divisional vice president sale and marketing endovascular avd elected corporate officer jared watkin to present senior vice president diabetes care elected corporate officer alejandro wellisch to present senior vice president established pharmaceutical latin america to general manager argentina bolivia paraguay and uruguay established pharmaceutical elected corporate officer randel woodgrift to present senior vice president crm to vice president global operation cardiovascular and neuromodulation to vice president operation and abbott vascular elected corporate officer philip boudreau to present vice president finance and controller to divisional vice president controller medical device to divisional vice president controller and commercial support point of care elected corporate officer part iiitem market for registrant common equity related stockholder matter and issuer purchase of equity securitiesprincipal marketthe principal market for abbott common share is the new york stock exchange under the symbol abt share are also listed on the chicago stock exchange and traded on various regional and electronic exchange outside the united state abbott share are listed on the six swiss exchange shareholdersthere were shareholder of record of abbott common share of december tax information for shareholdersin the illinois department of commerce and economic opportunity dceo designated abbott an illinois high impact business hib for period not to exceed twenty year in the dceo granted two year extension for abbott hib designation dividend paid by corporation that is designated hib and conduct business in foreign trade zone may be eligible for subtraction from base income for illinois income tax purpose abbott certified that the hib requirement were met for the calendar year ending december if you have any question please contact tax advisor issuer purchase of equity security total number of maximum number or total number share or unit approximate dollar value of of share average price purchased part of share or unit that may or unit paid per share publicly announced yet be purchased under the period purchased or unit plan or program plan or program october october november november december december total these share include the share deemed surrendered to abbott to pay the exercise price in connection with the exercise of employee stock option in october in november and in december these share do not include the share surrendered to abbott to satisfy tax withholding obligation in connection with the vesting of restricted stock or restricted stock unit on october the board of director authorized the repurchase of up to billion of abbott common share from time to time the plan on december the board of director authorized the repurchase of up to billion of abbott common share from time to time the plan the plan is in addition to the unused portion of the plan item management discussion and analysis of financial condition and result of operationsfinancial reviewabbott revenue are derived primarily from the sale of broad line of health care product under short term receivable arrangement patent protection and license technological and performance feature and inclusion of abbott product under contract most impact which product are sold price control competition and rebate most impact the net selling price of product and the measurement of net sale and cost is impacted by foreign currency translation abbott primary product are medical device diagnostic testing product nutritional product and branded generic pharmaceutical sale in international market comprise approximately percent of consolidated net sale in and the coronavirus covid pandemic affected abbott diversified health care business in various way is further described below some business have performed at the level required to successfully meet new demand others have faced challenge during period when the number of covid case significantly increased and still others have been relatively le impacted by the pandemic abbott diagnostics segment experienced the most significant change in sale from to result of the covid pandemic in and abbott mobilized it team across multiple front to develop and launch various new diagnostic test for covid in march rapid diagnostics launched molecular test to detect covid on it id now rapid point of care platform in the pursuant to an emergency use authorization eua in august abbott launched it binaxnow covid ag card test portable lateral flow rapid test to detect covid pursuant to an eua in the in december abbott received an eua in the for virtually guided at home use of it binaxnow covid ag card rapid test and launched the product for at home use in march abbott announced that it received an eua in the for it over the counter non prescription binaxnow covid ag self test for individual with or without symptom in the first quarter of abbott also received euas in the that allow the non prescription use of the binaxnow covid ag card home test and the binaxnow covid ag card test for professional use for individual with or without symptom outside the in september rapid diagnostics launched it panbio rapid antigen test to detect covid pursuant to ce mark in october abbott received approval by the world health organization for emergency use listing for the panbio antigen test in january abbott received ce mark for two new us of it panbio rapid antigen test asymptomatic testing and self swabbing under the supervision of healthcare worker in june abbott announced that it had received ce mark for it over the counter panbio covid antigen self test for individual with or without symptom in molecular diagnostics developed and launched molecular test to detect covid using polymerase chain reaction pcr method on it realtime lab based platform and it alinity system pursuant to euas in the and ce mark molecular diagnostics also developed and launched it multiplex molecular test on it alinity system to detect covid influenza influenza and respiratory syncytial virus rsv in one test this multiplex molecular test wa launched pursuant to ce mark in december and an eua in the in march in and core laboratory diagnostics developed and launched various lab based serology blood test on it architect and architect laboratory instrument and on it alinity system for the detection of an antibody to determine if someone wa previously infected with the virus the test were launched under euas in the and ce mark in and abbott covid testing related sale totaled approximately billion and billion respectively led by sale related to abbott binaxnow panbio and id now rapid testing platform volume were affected by fluctuation in the number of covid case especially in the over the course of the year in the second quarter of demand for covid test decreased from the previous quarter covid vaccine were administered covid case and hospitalization declined and the health authority updated it guidance on testing for fully vaccinated individual however in the second half of the delta and omicron variant of covid spread and the number of new covid case increased demand for rapid covid test increased significantly with respect to other product sold by the diagnostics segment demand for routine diagnostic testing generally fluctuated the number of covid case changed in various geographic region throughout the two year period in in addition to negatively impacting routine core diagnostic testing volume the pandemic negatively affected the number of cardiovascular and neuromodulation procedure performed by health care provider globally thereby reducing the demand for abbott cardiovascular and neuromodulation device and routine diagnostic test the decrease began in february in china that country implemented quarantine restriction and postponed non emergency health care activity the negative impact on cardiovascular and neuromodulation procedure and routine diagnostic test expanded to other country and geographic region covid spread geographically in the first half of and health care system in these country shifted their focus to fighting covid the extent of the impact and the timing of recovery in the number of procedure and routine testing in particular country or geographic region depended upon the progression of covid case in that country or region well the action taken by the government in that country related to covid in the recovery in procedure and routine testing volume in china began in march in other part of the world such the and europe volume improved across abbott hospital based business the second quarter progressed and the improvement continued in the third quarter however in the fourth quarter of the improving trend in the demand for procedure and routine testing flattened or were negatively impacted depending upon the business and the region many country including the experienced an increase in the number of covid case and hospitalization while routine diagnostic testing and cardiovascular and neuromodulation procedure volume were negatively impacted early in by elevated covid case rate overall volume improved over the course of the year until the latter part of when demand softened in several geography with the emergence of another variant while abbott branded generic pharmaceutical business wa also negatively affected by the pandemic in covid spread across emerging market country in the second and third quarter of volume recovered and grew in abbott nutritional and diabetes care business were the least affected by the pandemic is further discussed below abbott is continually monitoring the effect of the pandemic on it operation throughout the pandemic abbott ha continued to ensure that it operation throughout the world are aligned with the specific governmental order and guideline affecting each location abbott ha taken aggressive step to limit exposure to covid and enhance the safety of facility for it employee the demand for covid test ha been highly volatile abbott expects this volatility to continue the possible emergence and severity of new variant are unpredictable due to the unpredictability of the duration and impact of the covid pandemic the extent to which the pandemic will have material effect on abbott business financial condition or result of operation is uncertain while abbott and sale were most significantly affected by the covid pandemic the increase in total sale over the last three year also reflects the introduction of new product across various business well higher sale of various existing product sale in emerging market which represent approximately percent of total company sale increased percent in and percent in excluding the impact of foreign exchange emerging market include all country except the united state western europe japan canada australia and new zealand over the last three year abbott operating margin percentage of sale increased from percent in to percent in and percent in the increase in from reflects the impact of sale volume increase for covid test in rapid diagnostics and growth across virtually all of abbott business due in part to recovery from the covid pandemic partially offset by the impact of inflation and supply chain challenge on various manufacturing input and transportation cost an increase in restructuring cost and the unfavorable effect of foreign exchange the increase in reflects the sale volume increase in the rapid and molecular diagnostics business partially offset by lower medical device sale due to the impact of the pandemic and the unfavorable effect of foreign exchange in addition reduction in the cost associated with business acquisition and restructuring activity drove an improvement in operating margin from to in abbott experienced availability issue with some service and material used in it product to date abbott ha been able to manage the various supply chain challenge without significant supply disruption or shortage for service raw material and supply while abbott expects inflationary pressure on various raw material packaging material and transportation cost to continue in the impact of such cost increase is expected to be at least partially mitigated by price increase in certain business and the impact of continued gross margin improvement initiative to the extent that supply chain challenge in the industry in which abbott operates normalize over time this may lessen inflationary pressure with respect to the performance of each reportable segment over the last three year sale in the medical device segment excluding the impact of foreign exchange increased percent in and decreased percent in the sale increase in wa driven by double digit growth across all of abbott medical device division led by diabetes care structural heart and electrophysiology the sale decrease in wa driven by abbott cardiovascular and neuromodulation business due primarily to reduced procedure volume result of the covid pandemic these decrease were partially offset by double digit growth in diabetes care in operating earnings for the medical device segment increased percent the operating margin profile increased from percent of sale in to percent in primarily due to higher sale volume in diabetes care and abbott cardiovascular and neuromodulation business this growth wa partially offset by pricing pressure on drug eluting stent de result of market competition in the and other major market in key product approval in the medical device segment included ce mark in europe for navitor abbott latest generation transcatheter aortic valve implantation tavi system for patient with severe aortic stenosis who are at high or extreme surgical risk food and drug administration fda approval of the amplatzer amulet left atrial appendage occluder which offer immediate closure of the left atrial appendage an area in the heart where blood clot can form fda approval of the portico with flexnav tavi system to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open heart surgery and fda approval of the amplatzer talisman pfo occlusion system to treat people with patent foramen ovale small opening between the upper chamber of the heart who are at risk of recurrent ischemic stroke in abbott worldwide diagnostics business sale increased percent in and percent in excluding the impact of foreign exchange wa discussed above sale growth in wa driven by demand for abbott portfolio of rapid diagnostics test for covid and higher routine diagnostics testing in the core laboratory business partially offset by lower demand for abbott laboratory based test for covid in the molecular diagnostics business growth in wa driven by demand for abbott portfolio of covid diagnostics test across it rapid and lab based platform partially offset by lower volume of routine laboratory testing due to the pandemic abbott ha regulatory approval in the europe china and other market for the alinity and alinity instrument and ha continued to build it test menu for clinical chemistry and immunoassay diagnostics abbott ha obtained regulatory approval for the alinity instrument for hematology in europe and japan abbott ha also obtained regulatory approval in the europe and other market for the alinity blood screening and alinity molecular instrument and several testing assay in operating earnings for the diagnostics segment increased percent the operating margin profile increased from percent of sale in to percent in primarily due to higher sale in rapid diagnostics in and and increased routine diagnostics testing in in core laboratory diagnostics in abbott worldwide nutritional product business sale over the last three year were positively impacted by numerous new product introduction including the roll out of human milk oligosaccharide or hmo in infant formula that leveraged abbott strong brand sale over the last two year were also positively impacted by consumer interest in nutrient that help support their immune system excluding the impact of foreign exchange total adult nutrition sale increased percent in and percent in led by the continued growth of ensure abbott market leading complete and balanced nutrition brand and glucerna abbott market leading diabetes specific nutrition brand across several country excluding the impact of foreign exchange total pediatric nutrition sale increased percent in and percent in driven by the pedialyte pediasure and similac brand in the well infant and toddler product growth across several international market partially offset by challenging market dynamic in the infant category in greater china operating margin for the worldwide nutritional product business decreased from percent in to percent in the decrease wa driven by higher manufacturing and distribution cost including commodity price partially offset by the impact of gross margin improvement initiative the established pharmaceutical product segment focus on the sale of it product in emerging market excluding the impact of foreign exchange established pharmaceutical sale increased percent in and percent in the sale increase in and reflect higher sale in several geography including india china brazil and russia operating margin decreased from percent of sale in to percent in primarily due to the unfavorable impact of foreign exchange higher product cost and product mix partially offset by the impact of gross margin improvement initiative with respect to abbott financial position at december abbott cash and cash equivalent and short term investment total approximately billion compared to billion at december abbott long term debt and short term borrowing total billion and billion at december and respectively abbott declared dividend of per share in compared to per share in an increase of approximately percent dividend paid totaled billion in compared to billion in the year over year change in the amount of dividend paid primarily reflects the increase in the dividend rate in december abbott increased the company quarterly dividend by percent to per share from per share effective with the dividend paid in february in december abbott increased the company quarterly dividend by percent to per share from per share effective with the dividend paid in february in abbott will focus on continuing to meet the demand for covid test and will continue to invest in product development area that provide the opportunity for strong sustainable growth over the next several year in it diagnostics business abbott will continue to focus on driving market adoption and geographic expansion of it alinity suite of diagnostics instrument in the medical device segment abbott will focus on expanding it market position across the various business in it nutritionals business abbott will continue to focus on driving growth globally and further enhancing it portfolio with the introduction of line extension of it science based product in the established pharmaceutical business abbott will continue to focus on growing it business with the depth and breadth of it portfolio in emerging market critical accounting policiessales rebate in approximately percent of abbott consolidated gross revenue were subject to various form of rebate and allowance that abbott recorded reduction of revenue at the time of sale most of these rebate and allowance in are in the nutritional product and diabetes care business abbott provides rebate to state agency that administer the special supplemental nutrition program for woman infant and child wic wholesaler group purchasing organization and other government agency and private entity rebate amount are usually based upon the volume of purchase using contractual or statutory price for product factor used in the rebate calculation include the identification of which product have been sold subject to rebate which customer or government agency price term apply and the estimated lag time between sale and payment of rebate using historical trend adjusted for current change abbott estimate the amount of the rebate that will be paid and record the liability reduction of gross sale when abbott record it sale of the product settlement of the rebate generally occurs from one to six month after sale abbott regularly analyzes the historical rebate trend and make adjustment to reserve for change in trend and term of rebate program rebate and chargebacks charged against gross sale in and amounted to approximately billion billion and billion respectively or percent percent and percent of gross sale respectively based on gross sale of approximately billion billion and billion respectively subject to rebate one percentage point increase in the percentage of rebate to related gross sale would decrease net sale by approximately million in abbott considers one percentage point increase to be reasonably likely increase in the percentage of rebate to related gross sale other allowance charged against gross sale were approximately million million and million for cash discount in and respectively and million million and million for return in and respectively cash discount are known within to day of sale and therefore can be reliably estimated return can be reliably estimated because abbott historical return are low and because sale return term and other sale term have remained relatively unchanged for several period management analyzes the adequacy of ending rebate accrual balance each quarter in the domestic nutritional business management us both internal and external data available to estimate the accrual in the wic business estimate are required for the amount of wic sale within each state where abbott hold the wic contract the state where the sale is made which is the determining factor for the applicable rebated price is reliably determinable rebated price are based on contractually obligated agreement generally lasting period of two to four year except for change in contract price or transition period before or after change in the supplier for the wic business in state accrual are based on historical redemption rate and data from the department of agriculture usda and the state submitting rebate claim the usda which administers the wic program ha been making it data available for many year management also estimate the state processing lag time based on sale and claim data inventory in the retail distribution channel doe not vary substantially management ha access to several large customer inventory management data which allows management to make reliable estimate of inventory in the retail distribution channel at december abbott had wic business in state historically adjustment to prior year rebate accrual have not been material to net income abbott employ various technique to verify the accuracy of claim submitted to it and where possible work with the organization submitting claim to gain insight into change that might affect the rebate amount for government agency program the calculation of rebate involves interpretation of relevant regulation which are subject to challenge or change in interpretation income tax abbott operates in numerous country where it income tax return are subject to audit and adjustment because abbott operates globally the nature of the audit item is often complex and the objective of the government auditor can result in tax on the income in more than one country abbott employ internal and external tax professional to minimize audit adjustment amount where possible in accordance with the accounting rule relating to the measurement of tax contingency in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position and the measurement of the benefit is calculated the largest amount that is more than percent likely to be realized upon resolution of the benefit application of these rule requires significant amount of judgment in the abbott federal income tax return through are settled undistributed foreign earnings remain indefinitely reinvested in foreign operation determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in it foreign entity is not practicable pension and post employment benefit abbott offer pension benefit and post employment health care to many of it employee abbott engages outside actuary to assist in the determination of the obligation and cost under these program abbott must develop long term assumption the most significant of which are the health care cost trend rate discount rate and the expected return on plan asset the discount rate used to measure liability were determined based on high quality fixed income security that match the duration of the expected retiree benefit the health care cost trend rate represent abbott expected annual rate of change in the cost of health care benefit and are forward projection of health care cost of the measurement date difference between the assumed rate and the actual rate which will not be known for year can be significant in relation to the obligation and the annual cost recorded for these program the impact of higher interest rate and improved asset return during significantly decreased the net actuarial loss for these plan at december pretax net actuarial loss and prior service cost and credit recognized in accumulated other comprehensive income loss were net loss of billion for abbott defined benefit plan and net loss of million for abbott medical and dental plan actuarial loss and gain are amortized over the remaining service attribution period of the employee under the corridor method in accordance with the rule for accounting for post employment benefit difference between the expected long term return on plan asset and the actual annual return are amortized over five year period valuation of intangible asset abbott ha acquired and continues to acquire significant intangible asset that abbott record at fair value at the acquisition date transaction involving the purchase or sale of intangible asset occur with some frequency between company in the health care field and valuation are usually based on discounted cash flow analysis the discounted cash flow model requires assumption about the timing and amount of future net cash flow risk cost of capital terminal value and market participant each of these factor can significantly affect the value of the intangible asset abbott engages independent valuation expert who review abbott critical assumption and calculation for acquisition of significant intangible abbott review definite lived intangible asset for impairment each quarter using an undiscounted net cash flow approach if the undiscounted cash flow of an intangible asset are le than the carrying value of an intangible asset the intangible asset is written to it fair value which is usually the discounted cash flow amount where cash flow can not be identified for an individual asset the review is applied at the lowest group level for which cash flow are identifiable goodwill and indefinite lived intangible asset which relate to in process research and development acquired in business combination are reviewed for impairment annually or when an event that could result in impairment occurs at december goodwill amounted to billion and net intangible amounted to billion amortization expense in continuing operation for intangible asset amounted to billion in billion in and billion in there wa no reduction of goodwill relating to impairment in and litigation abbott account for litigation loss in accordance with financial accounting standard board fasb accounting standard codification asc no contingency under asc no loss contingency provision are recorded for probable loss at management best estimate of loss or when best estimate can not be made minimum loss contingency amount is recorded these estimate are often initially developed substantially earlier than the ultimate loss is known and the estimate are refined each accounting period additional information becomes known accordingly abbott is often initially unable to develop best estimate of loss and therefore the minimum amount which could be zero is recorded information becomes known either the minimum loss amount is increased resulting in additional loss provision or best estimate can be made also resulting in additional loss provision occasionally best estimate amount is changed to lower amount when event result in an expectation of more favorable outcome than previously expected abbott estimate the range of possible loss to be from approximately million to million for it legal proceeding and environmental exposure accrual of approximately million have been recorded at december for these proceeding and exposure these accrual represent management best estimate of probable loss defined by fasb asc no contingency result of operationssalesthe following table detail the component of sale growth by reportable segment for the last two year component of change total change price volume exchangetotal net sale total total international established pharmaceutical product segment nutritional product segment diagnostic product segment medical device segment the increase in total net sale in reflects volume growth across all of abbott segment in abbott covid testing related sale totaled approximately billion led by combined sale of approximately billion related to abbott binaxnow panbio and id now rapid testing platform in excluding the impact of covid testing related sale abbott total net sale increased percent excluding the impact of covid testing related sale and foreign exchange abbott total net sale in increased percent the price decline related to the diagnostic product segment in primarily reflects lower pricing for covid test the increase in total net sale in reflects volume growth in the diagnostics and nutritional product segment in covid testing related sale totaled approximately billion in medical device the impact of covid on abbott cardiovascular and neuromodulation business wa partially offset by double digit volume growth in diabetes care the price decline related to the medical device segment in and primarily reflect de pricing pressure result of market competition in the and other major market comparison of significant product and product group sale is follows percent change are versus the prior year and are based on unrounded number total impact of total change change exchange excl exchange dollar in million total established pharmaceutical key emerging market other nutritionals international pediatric nutritionals pediatric nutritionals international adult nutritionals adult nutritionals diagnostics core laboratory molecular point of care rapid diagnostics medical device rhythm management electrophysiology heart failure vascular structural heart neuromodulation diabetes care total impact of total change change exchange excl exchange dollar in million total established pharmaceutical key emerging market other nutritionals international pediatric nutritionals pediatric nutritionals international adult nutritionals adult nutritionals diagnostics core laboratory molecular point of care rapid diagnostics medical device rhythm management electrophysiology heart failure vascular structural heart neuromodulation diabetes care in order to compute result excluding the impact of exchange rate current year dollar sale are multiplied or divided appropriate by the current year average foreign exchange rate and then those amount are multiplied or divided appropriate by the prior year average foreign exchange rate total established pharmaceutical product sale increased percent in and percent in excluding the impact of foreign exchange the established pharmaceutical product segment is focused on several key emerging market including india russia china and brazil excluding the impact of foreign exchange total sale in these key emerging market increased percent in and percent in due to higher sale in several geography including india china russia and brazil excluding the impact of foreign exchange sale in established pharmaceutical other emerging market increased percent in and decreased percent in total nutritional product sale increased percent in and percent in excluding the impact of foreign exchange in international pediatric nutritional sale excluding the effect of foreign exchange decreased percent lower sale in china the middle east and various country in southeast asia were partially offset by higher volume sold in various country in latin america and europe the percent decrease in international pediatric nutritional sale excluding the effect of foreign exchange wa due to challenging market dynamic in the infant category in greater china that more than offset growth across abbott pediatric product in various country in southeast asia in the pediatric nutritional business sale increased percent in and percent in reflecting growth in pedialyte similac and pediasure in international adult nutritionals sale increased percent and percent in and respectively excluding the effect of foreign exchange due to continued growth of ensure and glucerna in several country adult nutritional sale increased percent in primarily due to growth of ensure and glucerna in adult nutritional sale increased percent primarily due to growth of ensure in the diagnostics segment core laboratory diagnostics sale increased percent in and decreased percent in excluding the effect of foreign exchange in growth wa driven by increased volume of routine diagnostic testing performed in hospital and other laboratory partially offset by lower sale of abbott laboratory based test for the detection of the igg and igm antibody which determine if someone wa previously infected with the covid virus in the decrease wa due to the lower volume of routine testing performed in hospital and other laboratory due to covid partially offset by sale of abbott covid laboratory based test for the detection of the igg and igm antibody core laboratory diagnostics covid testing related sale on abbott architect and alinity platform were million and million in and respectively in core laboratory diagnostics sale increased percent excluding covid testing related sale and increased percent excluding the impact of foreign exchange and covid testing related sale in molecular diagnostics sale decreased percent and increased percent in and respectively excluding the effect of foreign exchange in the decrease wa due to lower demand for abbott laboratory based molecular test for covid on it platform partially offset by growth in the base business from the continued roll out of the alinity platform in the increase reflects higher volume due to demand for abbott laboratory based molecular test for covid abbott received fda approval in march for it alinity molecular diagnostics system molecular diagnostics covid testing related sale were million and billion in and respectively in molecular diagnostics sale increased percent excluding covid testing related sale and increased percent excluding the impact of foreign exchange and covid testing related sale in rapid diagnostics sale increased percent and percent in and respectively excluding the effect of foreign exchange due to strong demand for abbott point of care covid molecular test on it id now platform and it binaxnow covid ag card test in the well international demand for covid rapid test on it panbio platform the sale increase for also included the recovery of routine diagnostic testing the sale increase for also included increased testing in the first quarter for the flu in the partially offset by the unfavorable impact of covid on routine diagnostic testing in rapid diagnostics covid testing related sale were billion and billion in and respectively in rapid diagnostics sale increased percent excluding covid testing related sale and increased percent excluding the impact of foreign exchange and covid testing related sale in medical device sale increased percent and decreased percent in and respectively excluding the effect of foreign exchange in the increase wa driven by double digit growth across all division led by diabetes care structural heart and electrophysiology in double digit growth in diabetes care wa more than offset by decrease in abbott cardiovascular and neuromodulation business due to the impact of covid and lower vascular sale in china in the fourth quarter of result of new national tender program the and growth in diabetes care revenue wa driven by continued growth of freestyle libre abbott continuous glucose monitoring system internationally and in the in freestyle libre sale totaled billion which reflected percent increase over excluding the effect of foreign exchange freestyle libre sale in were billion which reflected percent increase excluding the effect of foreign exchange over when sale totaled billion while procedure volume across abbott cardiovascular and neuromodulation business were negatively impacted early in by elevated covid case rate in certain country including the overall volume improved over the course of across various business the year over year increase in the various business reflect recovery from the level when the pandemic reduced procedure volume well sale growth from pre pandemic level in structural heart electrophysiology and heart failure excluding the effect of foreign exchange in january the center for medicare medicaid service expanded reimbursement coverage eligibility for mitraclip abbott market leading device for the minimally invasive treatment of mitral regurgitation mr leaky heart valve the growth in structural heart during wa broad based across several area of the business including mitraclip and triclip the world first minimally invasive clip based device for repair of leaky tricuspid heart valve which wa launched in europe in may abbott ha periodically sold product right to non strategic product and ha recorded the related gain in net sale in accordance with abbott revenue recognition policy discussed in note to the consolidated financial statement related net sale were not significant in and the expiration of license and patent protection can affect the future revenue and operating income of abbott there are no significant patent or license expiration in the next three year that are expected to materially affect abbott operating earningsgross profit margin were percent of net sale in percent in and percent in in the increase primarily reflects the effect of higher sale volume higher manufacturing utilization and the nonrecurrence of the impairment of intangible asset partially offset by increase in various manufacturing cost and the impact of higher restructuring charge in the decrease primarily reflects the mix of sale across abbott various business and operational inefficiency due to the impact of covid well the increase in intangible asset amortization the impairment of intangible asset and the unfavorable effect of foreign exchange on gross margin research and development expense were billion in and billion in both and the increase in spending wa primarily driven by higher spending on various project to advance product in development spending in wa relatively flat compared to the impact of the immediate expensing in of an asset valued at million that wa acquired in conjunction with the acquisition of cephea valve technology inc wa partially offset by the million impairment of an in process intangible asset in expense in also reflects lower integration and restructuring cost in related to partially offset by higher spending on various project selling general and administrative sg expense increased percent in due primarily to higher selling and marketing spending to drive growth across various business and the nonrecurrence of million of income in from litigation settlement the increase in also includes charge related to certain litigation sg expense were basically flat in compared to in the favorable effect of foreign exchange income of approximately million from litigation settlement in lower spending due to covid travel restriction and the impact of various cost saving initiative were offset by higher spending to drive growth in various business restructuringson may abbott management approved restructuring plan related to it diagnostic product segment to align it manufacturing network for covid diagnostic test with change in the second quarter in projected testing demand driven by several factor including significant reduction in case in the and other major developed country the accelerated rollout of covid vaccine globally and the health authority updated guidance on testing for fully vaccinated individual in the second quarter of abbott recorded charge of million under this plan in cost of product sold the charge recognized in the second quarter included fixed asset write down of million inventory related charge of million and other exit cost which included contract cancellation and employee related cost of million in the second half of the delta and omicron variant of covid spread and the number of new covid case increased significantly particularly in the demand for rapid covid test increased significantly result in the second half of abbott sold approximately million of inventory that wa previously estimated to have no net realizable value under the second quarter restructuring action in addition the estimate of other exit cost wa reduced by net million abbott fulfilled it purchase obligation under certain contract for which liability wa recorded in the second quarter or abbott settled with the counterparty in the second half of of december the accrued liability remaining in the consolidated balance sheet related to these action total million and primarily represent severance obligation from to abbott management approved restructuring plan part of the integration of the acquisition of st jude medical inc st jude medical into the medical device segment and alere inc alere into the diagnostic product segment in order to leverage economy of scale and reduce cost of december the accrued balance associated with these action wa million from to abbott recorded employee related severance and other charge totaling approximately million comprised of million in million in and million in approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense over the last three year of december the accrued liability remaining in the consolidated balance sheet related to these action total million from to abbott management approved plan to streamline operation in order to reduce cost and improve efficiency in various abbott business including the nutritional established pharmaceutical and vascular business of december the accrued balance associated with these action wa million from to abbott recorded employee related severance and other charge totaling approximately million comprised of million in and million in approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense over the two year of december the accrued liability remaining in the consolidated balance sheet related to these action total million in abbott management approved plan to streamline operation in order to reduce cost and improve efficiency in various abbott business including the diagnostics established pharmaceutical and nutritional business abbott recorded employee related severance and other charge of approximately million approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense of december the accrued liability remaining in the consolidated balance sheet related to these action total million and primarily represent severance obligation interest expense and interest income interest expense net decreased million in due to the reduction of interest expense driven by lower interest rate in the effect of higher cash and short term investment balance were more than offset by the impact of lower interest rate on interest income in in interest expense net decreased million due to reduction in interest expense resulting from the favorable impact of the euro debt financing in november the repayment of debt in december and lower interest rate environment in debt extinguishment costson december abbott redeemed the billion principal amount of it note due abbott incurred charge of million related to the early repayment of this debt other income expense netother income expense net includes income of approximately million million and million in and respectively related to the non service cost component of the net periodic benefit cost associated with the pension and post retirement medical plan other income expense net also includes gain on the sale of an equity method investment in and equity investment impairment that totaled approximately million in tax on earningsthe income tax rate on earnings from continuing operation were percent in percent in and percent in in tax on earnings from continuing operation include approximately million in excess tax benefit associated with share based compensation and approximately million of net tax benefit result of the resolution of various tax position related to prior year in tax on earnings from continuing operation include the recognition of approximately million of tax benefit associated with the impairment of certain asset approximately million of net tax benefit result of the resolution of various tax position related to prior year and approximately million in excess tax benefit associated with share based compensation in tax on earnings from continuing operation also include million increase to the transition tax liability associated with the tax cut and job act tcja the million increase to the transition tax liability wa the result of the resolution of various tax position related to prior year this adjustment increased the cumulative net tax expense related to the tcja to billion of december the remaining balance of abbott transition tax obligation is approximately million which will be paid over the next five year allowed by the tcja earnings from discontinued operation net of tax in reflect the recognition of million of net tax benefit primarily result of the resolution of various tax position related to prior year in tax on earnings from continuing operation included approximately million in excess tax benefit associated with share based compensation an million reduction of the transition tax and million of tax expense resulting from tax legislation enacted in the fourth quarter of in india the million reduction to the transition tax liability wa the result of the issuance of final transition tax regulation by the department of treasury in exclusive of these discrete item tax expense wa favorably impacted by lower tax rate and tax exemption on foreign income primarily derived from operation in puerto rico switzerland ireland the netherlands costa rica singapore and malta abbott benefit from combination of favorable statutory tax rule tax ruling grant and exemption in these tax jurisdiction see note to the consolidated financial statement for full reconciliation of the effective tax rate to the federal statutory rate research and development programsabbott currently ha numerous pharmaceutical medical device diagnostic and nutritional product in development research and development processin the established pharmaceutical segment the development process focus on the geographic expansion and continuous improvement of the segment existing product to provide benefit to patient and customer established pharmaceutical doe not actively pursue primary research development usually begin with work on existing product or after the acquisition of an advanced stage licensing opportunity depending upon the product the phase of development may include drug product development phase bioequivalence study to compare future established pharmaceutical brand with an already marketed compound with the same active pharmaceutical ingredient api phase ii study to test the efficacy of benefit in small group of patient phase iii study to broaden the testing to wider population that reflects the actual medical use phase iv and other post marketing study to obtain new clinical use data on existing product within approved indication the specific requirement scope of clinical trial for obtaining regulatory approval vary across different country and geographic region the process may range from one year for bioequivalence study project to six or more year for complex formulation new indication or geographic expansion in specific country such china in the diagnostics segment the phase of the research and development process include discovery which focus on identification of product that will address specific therapeutic area platform or unmet clinical need concept feasibility during which the material and manufacturing process are evaluated testing may include product characterization and analysis is performed to confirm clinical utility development during which extensive testing is performed to demonstrate that the product meet specified design requirement and that the design specification conform to user need and intended us the regulatory requirement for diagnostic product vary across different country and geographic region in the the fda classifies diagnostic product into class ii or iii and the classification determines the regulatory process for approval while the diagnostics segment ha product in all three class the vast majority of it product are categorized class or class ii submission of separate regulatory filing is not required for class product class ii device typically require pre market notification to the fda through regulatory filing known submission most class iii product are subject to the fda premarket approval pma requirement other class iii product such those used to screen blood require the submission and approval of biological license application bla in the european union eu diagnostic product are also categorized into different category and the regulatory process which ha been governed by the european in vitro diagnostic medical device directive depends upon the category with certain product category requiring review and approval by an independent company known notified body before the manufacturer can affix ce mark to the product to declare conformity to the directive other product only require self certification process in the eu adopted the new in vitro diagnostic regulation ivdr which replaces the existing directive in the eu for in vitro diagnostic product and imposes additional premarket and post market regulatory requirement on manufacturer of such product in december the ivdr wa amended to extend the regulation previous two year transition period by one to three year with the transition period extending to may for certain device however the amendment doe not delay the date of application of the ivdr which will take effect on may in the medical device segment the research and development process begin with research on specific technology that is evaluated for feasibility and commercial viability if the research program pass that hurdle it move forward into development the development process includes evaluation selection and qualification of product design completion of applicable clinical trial to test the product safety and efficacy and validation of the manufacturing process to demonstrate it repeatability and ability to consistently meet pre determined specification similar to the diagnostic product discussed above in the medical device are classified class ii or iii most of abbott medical device product are classified class ii device that follow the regulatory process or class iii device that are subject to the pma process in the eu medical device are also categorized into different class and the regulatory process which had been governed by the european medical device directive and the active implantable medical device directive varies by class in the second quarter of the eu adopted the new medical device regulation mdr which replaced the existing directive in the eu for medical device and imposes additional premarket and post market regulatory requirement on manufacturer of such product the mdr applies to manufacturer of may after four year transition period each product must bear ce mark to show compliance with the mdr some product require submission of design dossier to the appropriate regulatory authority for review and approval prior to ce marking of the device for other product the company is required to prepare technical file which includes testing result and clinical evaluation but can self certify it ability to apply the ce mark to the product outside the and the eu the regulatory requirement vary across different country and region after approval and commercial launch of some medical device post market trial may be conducted either due to conditional requirement of the regulatory market approval or with the objective of proving product superiority in the nutritional segment the research and development process generally focus on identifying and developing ingredient and product that address the nutritional need of particular population infant and adult or patient people with diabetes depending upon the country and or region if claim regarding product efficacy will be made clinical study typically must be conducted in the the fda requires that it be notified of proposed new formulation and formulation or packaging change related to infant formula product prior to the launch of an infant formula or product packaging change the company is required to obtain the fda confirmation that it ha no objection to the proposed product or packaging for other nutritional product notification or pre approval from the fda is not required unless the product includes new food additive in some country regulatory approval may be required for certain nutritional product including infant formula and medical nutritional product area of focusin and beyond abbott significant area of therapeutic focus will include the following established pharmaceutical abbott focus on building country specific portfolio made up of high quality medicine that meet the need of people in emerging market over the next several year abbott plan to expand it product portfolio in key therapeutic area with the aim of being among the first to launch new off patent and differentiated medicine in addition abbott continues to expand existing brand into new market implement product enhancement that provide value to patient and acquire strategic product and technology through licensing activity abbott is also actively working on the further development of several key brand such creon duphaston duphalac and influvac depending on the product the activity focus on development of new data market formulation delivery system or indication medical device abbott research and development program focus on cardiac rhythm management development of next generation rhythm management technology including advanced communication capability and leadless pacing therapy heart failure continued enhancement to abbott mechanical circulatory support and pulmonary artery pressure system including enhanced clinical performance and usability electrophysiology development of next generation technology in the area of ablation diagnostic mapping and visualization and recording vascular development of next generation technology for use in coronary and peripheral vascular procedure structural heart development of transcatheter and surgical device for the repair and replacement of heart valve and occlusion therapy for congenital heart defect and stroke risk reduction neuromodulation development of additional clinical evidence and next generation technology leveraging digital health to improve patient and physician engagement to treat chronic pain movement disorder and other indication diabetes care develop enhancement and additional indication for the freestyle libre platform of continuous glucose monitoring product to help patient improve their ability to manage diabetes and for use beyond diabetes nutritionals abbott is focusing it research and development spend on platform that span the pediatric and adult nutrition area gastro intestinal immunity health brain health mobility and metabolism and user experience platform numerous new product that build on advance in these platform are currently under development including clinical outcome testing and are expected to be launched over the coming year core laboratory diagnostics abbott continues to commercialize it next generation blood and plasma screening immunoassay clinical chemistry and hematology system along with assay including focus on unmet medical need in various area including infectious disease cardiac care metabolics and oncology well informatics solution to help optimize diagnostics laboratory performance and automation solution to increase efficiency in laboratory molecular diagnostics several new molecular in vitro diagnostic ivd test are in various stage of development and launch rapid diagnostics abbott research and development program focus on the development of diagnostic product for infectious disease cardiometabolic disease and toxicology in addition the diagnostics segment is pursuing the fda customary regulatory process for various covid test for which euas were obtained given the diversity of abbott business it intention to remain broad based health care company and the numerous source for potential future growth no individual project is expected to be material to cash flow or result of operation over the next five year factor considered included research and development expense projected to be incurred for the project over the next year relative to abbott total research and development expense well qualitative factor such marketplace perception and impact of new product on abbott overall market position there were no delay in abbott research and development activity that are expected to have material impact on operation while the aggregate cost to complete the numerous project currently in development is expected to be material the total cost to complete will depend upon abbott ability to successfully finish each project the rate at which each project advance and the ultimate timing for completion given the potential for significant delay and the risk of failure inherent in the development of medical device diagnostic and pharmaceutical product and technology it is not possible to accurately estimate the total cost to complete all project currently in development abbott plan to manage it portfolio of project to achieve research and development spending that will be competitive in each of the business in which it participates and such spending is targeted at approximately percent of total abbott sale in abbott doe not regularly accumulate or make management decision based on the total expense incurred for particular development phase in given period goodwillat december goodwill recorded result of business combination totaled billion goodwill is reviewed for impairment annually in the third quarter or when an event that could result in an impairment occurs using quantitative assessment to determine whether it is more likely than not that the fair value of any reporting unit is le than it carrying amount the income and market approach are used to calculate the fair value of each reporting unit the result of the last impairment test indicated that the fair value of each reporting unit wa substantially in excess of it carrying value financial conditioncash flownet cash from operating activity amounted to billion billion and billion in and respectively the increase in net cash from operating activity in wa primarily due to the favorable cash flow impact of higher segment operating earnings and improved working capital management partially offset by higher cash tax paid and the net impact of litigation settlement the increase in net cash from operating activity in wa primarily due to the favorable cash flow impact of higher segment operating earnings lower payment related to interest integration expense and restructuring action and the proceeds from litigation settlement partially offset by an increased investment in working capital and higher income tax payment substantial portion of abbott cash and cash equivalent at december is held by abbott affiliate outside of the if these fund were needed for operation in the abbott doe not expect to incur significant additional income tax in the future to repatriate these fund abbott funded million in million in and million in to defined benefit pension plan abbott expects pension funding of approximately million in for it pension plan abbott expects annual cash flow from operating activity to continue to exceed abbott capital expenditure and cash dividend debt and capitalat december abbott long term debt rating wa by standard poor corporation and by moody abbott expects to maintain an investment grade rating abbott ha readily available financial resource including unused line of credit that support commercial paper borrowing arrangement and provide abbott with the ability to borrow up to billion on an unsecured basis the line of credit are part of five year credit agreement revolving credit agreement that abbott entered into on november at that time abbott also terminated it revolving credit agreement there were no outstanding borrowing under the revolving credit agreement at the time of it termination any borrowing under the revolving credit agreement will mature and be payable on november any borrowing under the revolving credit agreement will bear interest at abbott option based on either base rate or eurodollar rate plus an applicable margin based on abbott credit rating in abbott repaid approximately million on short term facility upon maturity after the repayment abbott ha no short term debt and of december abbott total debt is billion in financing activity related to the issuance and repayment of long term debt included the following on june abbott completed the issuance of billion aggregate principal amount of senior note consisting of million of it note due and million of it note due on september abbott repaid the billion outstanding principal amount of it note due upon maturity the repayment equated to approximately billion in abbott committed to reducing it debt level which had increased part of the acquisition of st jude medical and alere in on february abbott redeemed the million outstanding principal amount of it note due in september the board of director authorized the early redemption of up to billion of outstanding long term note this bond redemption authorization superseded the board previous authorization under which million had not yet been redeemed on december abbott redeemed the billion outstanding principal amount of it note due of the billion authorization billion remains available of december on november abbott wholly owned subsidiary abbott ireland financing dac completed euro debt offering of billion of long term debt the proceeds equated to approximately billion the note are guaranteed by abbott on november abbott borrowed billion under year term loan and designated the yen denominated loan hedge of it net investment in certain foreign subsidiary the term loan bear interest at tibor plus fixed spread and the interest rate is reset quarterly the proceeds equated to approximately million in total these transaction resulted in the repayment of approximately of billion of debt net of borrowing in september the board of director authorized the repurchase of up to billion of abbott common share from time to time under the program authorized in abbott repurchased million share at cost of billion from through million share at cost of million in and million share at cost of million in for total of approximately billion in october the board of director authorized the repurchase of up to billion of abbott common share from time to time in abbott repurchased million of it common share for billion which fully utilized the authorization remaining under the share repurchase program and portion of the authorization in december the board of director authorized the repurchase of up to billion of abbott common share from time to time the new authorization is in addition to the billion unused portion of the share repurchase program authorized in abbott declared dividend of per share in compared to per share in an increase of approximately percent dividend paid were billion in compared to billion in the year over year change in dividend paid primarily reflects the impact of the increase in the dividend rate working capitalworking capital wa billion at december and billion at december the increase wa due in large part to the higher level of cash and cash equivalent which wa due primarily to the increase in cash generated from operating activity partially offset by the classification of million of senior note due current liability at december and an increase in account payable associated with the growth of the business abbott monitor the credit worthiness of customer and establishes an allowance that reflects the current estimate of credit loss expected to be incurred over the life of the financial asset abbott considers various factor in establishing monitoring and adjusting it allowance for doubtful account including the aging of the account and aging trend the historical level of charge offs and specific exposure related to particular customer abbott also monitor other risk factor and forward looking information such country risk when determining credit limit for customer and establishing adequate allowance capital expenditurescapital expenditure of billion in billion in and billion in were principally for upgrading and expanding manufacturing and research and development facility and equipment in various segment investment in information technology and laboratory instrument placed with customer the increase in capital expenditure primarily reflects the building of capacity for the manufacture of covid diagnostics test contractual obligation abbott belief that it available cash and cash equivalent along with it ability to generate operating cash flow and continued access to debt market are sufficient to fund existing and planned cash requirement abbott material cash requirement include the following contractual obligation debt principal payment required on long term debt outstanding at december are million in billion in billion in billion in billion in and billion in and thereafter interest payment required on long term debt outstanding at december are million in million in million in million in million in and billion in and thereafter operating lease of december estimated contractual obligation for operating lease payment were billion with million due within month in addition abbott enters into purchase commitment in the normal course of business to meet operational and capital expenditure requirement the majority of outstanding purchase commitment generally do not extend past one year contingent obligationsabbott periodically acquires business or product right in which abbott agrees to pay contingent consideration based on attaining certain threshold or based on the occurrence of certain event legislative issuesabbott primary market are highly competitive and subject to substantial government regulation throughout the world abbott expects debate to continue over the availability method of delivery and payment for health care product and service it is not possible to predict the extent to which abbott or the health care industry in general might be adversely affected by these factor in the future more complete discussion of these factor is contained in item business and item risk factor recently issued accounting standardsin december the financial accounting standard board fasb issued accounting standard update asu income tax topic simplifying the accounting for income tax which among other thing eliminates certain exception in the current rule regarding the approach for intraperiod tax allocation and the methodology for calculating income tax in an interim period and clarifies the accounting for transaction that result in step up in the tax basis of goodwill abbott adopted the standard on january the new standard not have an impact on it consolidated financial statement in june the fasb issued asu financial instrument credit loss which change the methodology to be used to measure credit loss for certain financial instrument and financial asset including trade receivables the new methodology requires the recognition of an allowance that reflects the current estimate of credit loss expected to be incurred over the life of the financial asset abbott adopted the standard on january and recorded cumulative adjustment that wa not significant to earnings employed in the business in the consolidated balance sheet private security litigation reform act of caution concerning forward looking statementsunder the safe harbor provision of the private security litigation reform act of abbott caution investor that any forward looking statement or projection made by abbott including those made in this document are subject to risk and uncertainty that may cause actual result to differ materially from those projected economic competitive governmental technological and other factor that may affect abbott operation are discussed in item risk factor item quantitative and qualitative disclosure about market riskfinancial instrument and risk managementmarket price sensitive investmentsthe fair value of equity security held by abbott with readily determinable fair value wa approximately million and million of december and respectively these equity security are subject to potential change in fair value hypothetical percent decrease in the share price of these investment would decrease their fair value at december by approximately million change in the fair value of these security are recorded in earnings the fair value of investment in mutual fund that are held in rabbi trust for the purpose of paying benefit under deferred compensation plan wa approximately million and million of december and respectively change in the fair value of these investment well an offsetting change in the benefit obligation are recorded in earnings non publicly traded equity securitiesabbott hold equity security that are not traded on public stock exchange the carrying value of these investment wa million and million of december and respectively no individual investment is recorded at value in excess of million abbott measure these investment at cost minus impairment if any plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer interest rate sensitive financial instrumentsat december and abbott had interest rate hedge contract totaling billion to manage it exposure to change in the fair value of debt the effect of these hedge is to change the fixed interest rate to variable rate for the portion of the debt that is hedged abbott doe not use derivative financial instrument such interest rate swap to manage it exposure to change in interest rate for it investment security the fair value of long term debt at december and amounted to billion and billion respectively average interest rate of and of december and respectively with maturity through at december and the fair value of current and long term investment security amounted to approximately billion and billion respectively hypothetical basis point change in the interest rate would not have material effect on cash flow income or fair value foreign currency sensitive financial instrumentscertain abbott foreign subsidiary enter into foreign currency forward exchange contract to manage exposure to change in foreign exchange rate for anticipated intercompany purchase by those subsidiary whose functional currency are not the dollar these contract are designated cash flow hedge of the variability of the cash flow due to change in foreign currency exchange rate and are marked to market with the resulting gain or loss reflected in accumulated other comprehensive income loss gain or loss will be included in cost of product sold at the time the product are sold generally within the next twelve to eighteen month at december and abbott held billion and billion respectively of such contract contract held at december will mature in or depending upon the contract contract held at december matured in or will mature in depending upon the contract abbott enters into foreign currency forward exchange contract to manage it exposure to foreign currency denominated intercompany loan and trade payable and third party trade payable and receivables the contract are marked to market and resulting gain or loss are reflected in income and are generally offset by loss or gain on the foreign currency exposure being managed at december and abbott held billion and billion respectively of such contract which mature in the next month in november abbott borrowed billion under year term loan and designated the yen denominated loan hedge of the net investment in certain foreign subsidiary the proceeds equated to approximately million the value of this long term debt wa approximately million and million of december and december respectively the change in the value of the debt which is due to change in foreign exchange rate wa recorded in accumulated other comprehensive income loss net of tax the following table reflects the total foreign currency forward exchange contract outstanding at december and weighted fair and weighted fair and average carrying value average carrying value contract exchange receivable contract exchange receivable dollar in million amount rate payable amount rate payable primarily dollar to be exchanged for the following currency euro chinese yuan japanese yen all other currency total item financial statement and supplementary data pageconsolidated statement of earnings statement of comprehensive income statement of cash flow balance sheet statement of shareholder investment to consolidated financial statement report on internal control over financial reporting of independent registered public accounting firm pcaob id of independent registered public accounting firm abbott laboratory and subsidiariesconsolidated statement of earnings in million except per share data year ended december sale of product sold excluding amortization of intangible asset of intangible asset and development general and administrative operating cost and expense earnings expense income net foreign exchange gain loss extinguishment cost income expense net earnings from continuing operation before tax on earnings from continuing operation earnings from continuing operation net earnings from discontinued operation net of tax net earnings basic earnings per common share continuing operation operation net earnings diluted earnings per common share continuing operation operation net earnings average number of common share outstanding used for basic earnings per common share common stock option number of common share outstanding plus dilutive common stock option common stock option having no dilutive effect the accompanying note to consolidated financial statement are an integral part of this statement abbott laboratory and subsidiariesconsolidated statement of comprehensive income in million year ended december earnings currency translation gain loss adjustment net actuarial gain loss and prior service cost and credit and amortization of net actuarial loss and prior service cost and credit net of tax of in in and in net gain loss on derivative instrument designated cash flow hedge net of tax of in in and in other comprehensive income loss comprehensive income supplemental accumulated other comprehensive income loss information net of tax of december cumulative foreign currency translation loss adjustment net actuarial loss and prior service cost and credit cumulative gain loss on derivative instrument designated cash flow hedge accumulated other comprehensive income loss the accompanying note to consolidated financial statement are an integral part of this statement abbott laboratory and subsidiariesconsolidated statement of cash flow in million year ended december flow from used in operating activity net earnings to reconcile earnings to net cash from operating activity depreciation of intangible asset based compensation and financing loss net on extinguishment of debt receivables inventory prepaid expense and other asset trade account payable and other liability tax net cash from operating activity cash flow from used in investing activity acquisition of property and equipment acquisition of business and technology net of cash acquired proceeds from business disposition of investment security proceeds from sale of investment security cash from used in investing activity cash flow from used in financing activity proceeds from issuance of repayment of short term debt net and other proceeds from issuance of long term debt and debt with maturity over month of long term debt and debt with maturity over month purchase of common share proceeds from stock option exercised paid other net cash from used in financing activity effect of exchange rate change on cash and cash equivalent net increase decrease in cash and cash equivalent and cash equivalent beginning of year and cash equivalent end of year supplemental cash flow information income tax paid paid the accompanying note to consolidated financial statement are an integral part of this statement abbott laboratory and subsidiariesconsolidated balance sheet dollar in million december current asset cash and cash equivalent primarily bank time deposit and treasury bill receivables le allowance of finished product in process inventory prepaid expense and receivables current asset and equipment at cost land in progress accumulated depreciation and amortization property and equipment asset net of amortization income tax and other asset abbott laboratory and subsidiariesconsolidated balance sheet dollar in million december and shareholder investment current liability short term borrowing account payable wage and commission accrued liability payable tax payable portion of long term debt current liability term debt employment obligation and other long term liability and contingency shareholder investment preferred share one dollar par value authorized share none issued common share without par value authorized share issued at stated capital amount share share held in treasury at cost share earnings employed in the business other comprehensive income loss total abbott shareholder investment interest in subsidiary shareholder investment the accompanying note to consolidated financial statement are an integral part of this statement abbott laboratory and subsidiariesconsolidated statement of shareholder investment in million except share and per share data year ended december share beginning of year share under incentive stock program share based compensation of restricted stock award end of year share common share held in treasury beginning of year share issued under incentive stock program share share end of year share earnings employed in the business beginning of year of adoption of new accounting standard net earnings dividend declared on common share per share effect of common and treasury share transaction end of year accumulated other comprehensive income loss beginning of year other comprehensive income loss end of year noncontrolling interest in subsidiary beginning of year interest share of income business combination net of distribution and share repurchase of year the accompanying note to consolidated financial statement are an integral part of this statement abbott laboratory and subsidiariesnotes to consolidated financial statementsnote summary of significant accounting policiesnature of business abbott principal business is the discovery development manufacture and sale of broad line of health care product basis of consolidation the consolidated financial statement include the account of the parent company and subsidiary after elimination of intercompany transaction use of estimate the consolidated financial statement have been prepared in accordance with generally accepted accounting principle in the united state and necessarily include amount based on estimate and assumption by management actual result could differ from those amount significant estimate include amount for sale rebate income tax pension and other post employment benefit valuation of intangible asset litigation derivative financial instrument and inventory and account receivable exposure foreign currency translation the statement of earnings of foreign subsidiary whose functional currency are other than the dollar are translated into dollar using average exchange rate for the period the net asset of foreign subsidiary whose functional currency are other than the dollar are translated into dollar using exchange rate of the balance sheet date the dollar effect that arise from translating the net asset of these subsidiary at changing rate are recorded in the foreign currency translation adjustment account which is included in equity component of accumulated other comprehensive income loss transaction gain and loss are recorded on the net foreign exchange gain loss line of the consolidated statement of earnings revenue recognition revenue from product sale is recognized upon the transfer of control which is generally upon shipment or delivery depending on the delivery term set forth in the customer contract provision for discount rebate and sale incentive to customer and return and other adjustment are provided for in the period the related sale are recorded sale incentive to customer are not material historical data is readily available and reliable and is used for estimating the amount of the reduction in gross sale revenue from the launch of new product from an improved version of an existing product or for shipment in excess of customer normal requirement are recorded when the condition noted above are met in those situation management record return reserve for such revenue if necessary in certain of abbott business primarily within diagnostics abbott participates in selling arrangement that include multiple performance obligation instrument reagent procedure and service agreement the total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling price of the promised good or service underlying each performance obligation sale of product right for marketable product are recorded revenue upon disposition of the right income tax deferred income tax are provided for the tax effect of difference between the tax base of asset and liability and their reported amount in the financial statement at the enacted statutory rate to be in effect when the tax are paid no additional income tax have been provided for any remaining undistributed foreign earnings not subject to the transition tax related to the tax cut and job act tcja or any additional outside basis difference that exist these amount continue to be indefinitely reinvested in foreign operation effective for fiscal year beginning after december the tcja subject taxpayer to tax on global intangible low taxed income gilti earned by certain foreign subsidiary abbott treat the gilti tax period expense and provides for the tax in the year that the tax is incurred interest and penalty on income tax obligation are included in tax on earnings earnings per share unvested restricted stock unit and award that contain non forfeitable right to dividend are treated participating security and are included in the computation of earnings per share under the two class method under the two class method net earnings are allocated between common share and participating security earnings from continuing operation allocated to common share in and were billion billion and billion respectively net earnings allocated to common share in and were billion billion and billion respectively pension and post employment benefit abbott accrues for the actuarially determined cost of pension and post employment benefit over the service attribution period of the employee abbott must develop long term assumption the most significant of which are the health care cost trend rate discount rate and the expected return on plan asset difference between the expected long term return on plan asset and the actual return are amortized over five year period actuarial loss and gain are amortized over the remaining service attribution period of the employee under the corridor method abbott laboratory and subsidiariesnotes to consolidated financial statement continued note summary of significant accounting policy continued fair value measurement for asset and liability that are measured using quoted price in active market total fair value is the published market price per unit multiplied by the number of unit held without consideration of transaction cost asset and liability that are measured using significant other observable input are valued by reference to similar asset or liability adjusted for contract restriction and other term specific to that asset or liability for these item significant portion of fair value is derived by reference to quoted price of similar asset or liability in active market for all remaining asset and liability fair value is derived using fair value model such discounted cash flow model or black scholes model purchased intangible asset are recorded at fair value the fair value of significant purchased intangible asset is based on independent appraisal abbott us discounted cash flow model to value intangible asset the discounted cash flow model requires assumption about the timing and amount of future net cash flow risk the cost of capital terminal value and market participant intangible asset are reviewed for impairment on quarterly basis goodwill and indefinite lived intangible asset are tested for impairment at least annually share based compensation the fair value of stock option and restricted stock award and unit are amortized over their requisite service period which could be shorter than the vesting period if an employee is retirement eligible with charge to compensation expense litigation abbott account for litigation loss in accordance with financial accounting standard board fasb accounting standard codification asc no contingency under asc no loss contingency provision are recorded for probable loss at management best estimate of loss or when best estimate can not be made minimum loss contingency amount is recorded legal fee are recorded incurred cash cash equivalent and investment cash equivalent consist of bank time deposit government security money market fund and treasury bill with original maturity of three month or le abbott hold certain investment with carrying value of million that are accounted for under the equity method of accounting investment held in rabbi trust and investment in publicly traded equity security are recorded at fair value and change in fair value are recorded in earnings investment in equity security that are not traded on public stock exchange are recorded at cost minus impairment if any plus or minus change resulting from observable price change in orderly transaction for identical or similar investment of the same issuer trade receivable valuation account receivable are stated at the net amount expected to be collected the allowance for doubtful account reflects the current estimate of credit loss expected to be incurred over the life of the account receivable abbott considers various factor in establishing monitoring and adjusting it allowance for doubtful account including the aging of the account and aging trend the historical level of charge offs and specific exposure related to particular customer abbott also monitor other risk factor and forward looking information such country risk when determining credit limit for customer and establishing adequate allowance account receivable are charged off after all reasonable mean to collect the full amount including litigation where appropriate have been exhausted inventory inventory are stated at the lower of cost first in first out basis or net realizable value cost includes material and conversion cost property and equipment depreciation and amortization are provided on straight line basis over the estimated useful life of the asset the following table show estimated useful life of property and equipment classification estimated useful livesbuildings to yearsequipment to year product liability abbott accrues for product liability claim when it is probable that liability ha been incurred and the amount of the liability can be reasonably estimated based on existing information the liability are adjusted quarterly additional information becomes available product liability loss are self insured abbott laboratory and subsidiariesnotes to consolidated financial statement continued note summary of significant accounting policy continued research and development cost internal research and development cost are expensed incurred clinical trial cost incurred by third party are expensed the contracted work is performed where contingent milestone payment are due to third party under research and development arrangement the milestone payment obligation are expensed when the milestone result are achieved acquired in process and collaboration research and development ipr the initial cost of right to ipr project obtained in an asset acquisition are expensed ipr unless the project ha an alternative future use these cost include initial payment incurred prior to regulatory approval in connection with research and development collaboration agreement that provide right to develop manufacture market and or sell pharmaceutical or medical device product the fair value of ipr project acquired in business combination are capitalized and accounted for indefinite lived intangible asset until completed and are then amortized over the remaining useful life collaboration are not significant concentration of risk and guarantee due to the nature of it operation abbott is not subject to significant concentration risk relating to customer product or geographic location product warranty are not significant abbott ha no material exposure to off balance sheet arrangement no special purpose entity activity that include non exchange traded contract accounted for at fair value abbott periodically acquires business or product right in which abbott agrees to pay contingent consideration based on attaining certain threshold or based on the occurrence of certain event note new accounting standardsrecently adopted accounting standardsin june the fasb issued accounting standard update asu financial instrument credit loss which change the methodology to be used to measure credit loss for certain financial instrument and financial asset including trade receivables the new methodology requires the recognition of an allowance that reflects the current estimate of credit loss expected to be incurred over the life of the financial asset abbott adopted the standard on january and recorded cumulative adjustment that wa not significant to earnings employed in the business in the consolidated balance sheet in december the fasb issued asu income tax topic simplifying the accounting for income tax which among other thing eliminates certain exception in the current rule regarding the approach for intraperiod tax allocation and the methodology for calculating income tax in an interim period and clarifies the accounting for transaction that result in step up in the tax basis of goodwill abbott adopted the standard on january the new standard did not have an impact on it consolidated financial statement note revenueabbott revenue are derived primarily from the sale of broad line of health care product under short term receivable arrangement patent protection and license technological and performance feature and inclusion of abbott product under contract most impact which product are sold price control competition and rebate most impact the net selling price of product and foreign currency translation impact the measurement of net sale and cost abbott product are generally sold directly to retailer wholesaler distributor hospital health care facility laboratory physician office and government agency throughout the world abbott ha four reportable segment established pharmaceutical product diagnostic product nutritional product and medical device abbott laboratory and subsidiariesnotes to consolidated financial statement continued note revenue continued the following table provide detail by sale category in million int total int total int totalestablished pharmaceutical product key emerging market nutritionals pediatric nutritionals nutritionals diagnostics core laboratory of care diagnostics medical device rhythm management failure heart care other total abbott recognizes revenue from product sale upon the transfer of control which is generally upon shipment or delivery depending on the delivery term set forth in the customer contract for maintenance agreement that provide service beyond abbott standard warranty and other service agreement revenue is recognized ratably over the contract term time based measure of progress appropriately reflects the transfer of service to the customer payment term between abbott and it customer vary by the type of customer country of sale and the product or service offered the term between invoicing and the payment due date is not significant management exercise judgment in estimating variable consideration provision for discount rebate and sale incentive to customer and return and other adjustment are provided for in the period the related sale are recorded sale incentive to customer are not material historical data is readily available and reliable and is used for estimating the amount of the reduction in gross sale abbott provides rebate to government agency wholesaler group purchasing organization and other private entity abbott laboratory and subsidiariesnotes to consolidated financial statement continued note revenue continued rebate amount are usually based upon the volume of purchase using contractual or statutory price for product factor used in the rebate calculation include the identification of which product have been sold subject to rebate which customer or government agency price term apply and the estimated lag time between sale and payment of rebate using historical trend adjusted for current change abbott estimate the amount of the rebate that will be paid and record the liability reduction of gross sale when abbott record it sale of the product settlement of the rebate generally occurs from one to six month after sale abbott regularly analyzes the historical rebate trend and make adjustment to reserve for change in trend and term of rebate program historically adjustment to prior year rebate accrual have not been material to net income other allowance charged against gross sale include cash discount and return which are not significant cash discount are known within to day of sale and therefore can be reliably estimated return can be reliably estimated because abbott historical return are low and because sale return term and other sale term have remained relatively unchanged for several period product warranty are also not significant abbott also applies judgment in determining the timing of revenue recognition related to contract that include multiple performance obligation the total transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative standalone selling price of the promised good or service underlying each performance obligation for good or service for which observable standalone selling price are not available abbott us an expected cost plus margin approach to estimate the standalone selling price of each performance obligation remaining performance obligationsas of december the estimated revenue expected to be recognized in the future related to performance obligation that are unsatisfied or partially unsatisfied wa approximately billion in the diagnostic product segment and approximately million in the medical device segment abbott expects to recognize revenue on approximately percent of these remaining performance obligation over the next month approximately percent over the subsequent month and the remainder thereafter these performance obligation primarily reflect the future sale of reagent consumables in contract with minimum purchase obligation extended warranty or service obligation related to previously sold equipment and remote monitoring service related to previously implanted device abbott ha applied the practical expedient described in asc and ha not included remaining performance obligation related to contract with original expected duration of one year or le in the amount above asset recognized for cost to obtain contract with customerabbott ha applied the practical expedient in asc and record an expense the incremental cost of obtaining contract with customer in the period of occurrence when the amortization period of the asset that abbott otherwise would have recognized is one year or le upfront commission fee paid to sale personnel result of obtaining or renewing contract with customer are incremental to obtaining the contract abbott capitalizes these amount contract cost capitalized commission fee are amortized based on the contract duration to which the asset relate which range from two to ten year the amount of december and were not significant additionally the cost of transmitter provided to customer that use abbott remote monitoring service with respect to certain medical device are capitalized contract cost capitalized transmitter cost are amortized based on the timing of the transfer of service to which the asset relate which typically range from eight to ten year the amount of december and were not significant other contract asset and liabilitiesabbott discloses trade receivables separately in the consolidated balance sheet at the net amount expected to be collected contract asset primarily relate to abbott conditional right to consideration for work completed but not billed at the reporting date contract asset at the beginning and end of the period well the change in the balance were not significant abbott laboratory and subsidiariesnotes to consolidated financial statement continued note revenue continued contract liability primarily relate to payment received from customer in advance of performance under the contract abbott contract liability arise primarily in the medical device reportable segment when payment is received upfront for various multi period extended service arrangement change in the contract liability during the period are follows in million contract liability balance at december unearned revenue from cash received during the period revenue recognized related to contract liability balance balance at december revenue from cash received during the period recognized related to contract liability balance balance at december note supplemental financial informationother income expense net for and includes approximately million million and million of income respectively related to the non service cost component of the net periodic benefit cost associated with the pension and post retirement medical plan the following summarizes the activity related to the allowance for doubtful account in million allowance for doubtful account balance at december of adopting asu charge to income charged off and other deduction balance at december charge to income charged off and other deduction balance at december the allowance for doubtful account reflects the current estimate of credit loss expected to be incurred over the life of the account receivable abbott considers various factor in establishing monitoring and adjusting it allowance for doubtful account including the aging of the account and aging trend the historical level of charge offs and specific exposure related to particular customer abbott also monitor other risk factor and forward looking information such country risk when determining credit limit for customer and establishing adequate allowance the detail of various balance sheet component is follows december december in million term investment equity security the decrease in abbott long term investment of december versus the balance of december primarily relates to the sale of an equity method investment partially offset by the acquisition of additional investment abbott laboratory and subsidiariesnotes to consolidated financial statement continued note supplemental financial information continued abbott equity security of december and december include million and million respectively of investment in mutual fund that are held in rabbi trust acquired part of the st jude medical inc st jude medical business acquisition these investment which are specifically designated available for the purpose of paying benefit under deferred compensation plan are not available for general corporate purpose and are subject to creditor claim in the event of insolvency abbott also hold certain investment of december with carrying value of million that are accounted for under the equity method of accounting and other equity investment with carrying value of million that do not have readily determinable fair value an approximately million impairment of an investment wa recorded in for which abbott had previously recorded an unrealized gain of approximately million in in september abbott acquired percent of walk vascular llc walk vascular commercial stage medical device company with minimally invasive thrombectomy system designed to remove peripheral blood clot walk vascular peripheral thrombectomy system will be incorporated into abbott existing endovascular portfolio the purchase price the allocation of acquired asset and liability and the revenue and net income contributed by walk vascular since the date of acquisition are not material to abbott consolidated financial statement in in conjunction with the acquisition of cephea valve technology inc abbott acquired research development asset valued at million which wa immediately expensed the million of expense wa recorded in the research and development line of abbott consolidated statement of earnings december december in million accrued liability accrued rebate payable to government agency other rebate other accrued wholesaler chargeback rebate of million and million at december and respectively are netted in trade receivables because abbott customer are invoiced at higher catalog price but only remit to abbott their contract price for the product december december in million employment obligation and other long term liability defined benefit pension plan and post employment medical and dental plan for significant plan income tax lease liability other includes approximately million and million of net unrecognized tax benefit in and respectively abbott laboratory and subsidiariesnotes to consolidated financial statement continued note accumulated other comprehensive income loss the component of the change in accumulated other comprehensive income loss from continuing operation net of income tax are follows cumulative gain loss cumulative net actuarial on derivative foreign loss and instrument currency prior service designated translation cost and cash flow in million adjustment credit hedge totalbalance at december other comprehensive income loss before reclassification income loss amount reclassified from accumulated other comprehensive income current period other comprehensive income loss balance at december other comprehensive income loss before reclassification income loss amount reclassified from accumulated other comprehensive income current period other comprehensive income loss at december income loss amount reclassified from accumulated other comprehensive income related to cash flow hedge are recorded cost of product sold net actuarial loss and prior service cost is included component of net periodic benefit cost see note for additional information note goodwill and intangible assetsthe total amount of goodwill reported wa billion at december and billion at december foreign currency translation adjustment decreased goodwill by million in and increased goodwill by million in the amount of goodwill related to reportable segment at december wa billion for the established pharmaceutical product segment million for the nutritional product segment billion for the diagnostic product segment and billion for the medical device segment there were no reduction of goodwill relating to impairment in and indefinite lived intangible asset which relate to ipr acquired in business combination were approximately million and billion at december and respectively the decrease is due to ipr asset primarily related to the medical device segment that became amortizable in partially offset by an increase of approximately million related to recent acquisition in million impairment of an ipr intangible asset related to the medical device segment wa recorded in the research and development line of abbott consolidated statement of earnings the gross amount of amortizable intangible asset primarily product right and technology wa billion and billion of december and respectively and accumulated amortization wa billion and billion of december and respectively amortizable intangible asset increased by approximately million result of recent acquisition and the additional asset are being amortized over year foreign currency translation adjustment decreased intangible asset by million in and increased intangible asset by million in in asset impairment related to the established pharmaceutical product segment decreased intangible asset by million in asset impairment related to the medical device segment decreased intangible asset by million the impairment were recorded in the cost of product sold excluding amortization of intangible asset line of abbott consolidated statement of earnings the estimated annual amortization expense for intangible asset recorded at december is approximately billion in billion in billion in billion in and billion in amortizable intangible asset are amortized over to year abbott laboratory and subsidiariesnotes to consolidated financial statement continued note restructuring planson may abbott management approved restructuring plan related to it diagnostic product segment to align it manufacturing network for covid diagnostic test with change in the second quarter in projected testing demand driven by several factor including significant reduction in case in the and other major developed country the accelerated rollout of covid vaccine globally and the health authority updated guidance on testing for fully vaccinated individual in the second quarter of abbott recorded charge of million under this plan in cost of product sold the charge recognized in the second quarter included fixed asset write down of million inventory related charge of million and other exit cost which included contract cancellation and employee related cost of million in the second half of the delta and omicron variant of covid spread and the number of new covid case increased significantly particularly in the demand for rapid covid test increased significantly result in the second half of abbott sold approximately million of inventory that wa previously estimated to have no net realizable value under the second quarter restructuring action in addition the estimate of other exit cost wa reduced by net million abbott fulfilled it purchase obligation under certain contract for which liability wa recorded in the second quarter or abbott settled with the counterparty in the second half of the following summarizes the activity related to this restructuring action and the status of the related accrual of december inventory related fixed asset other exit in million charge write down cost totalrestructuring charge recorded in other non cash accrued balance at december from to abbott management approved restructuring plan part of the integration of the acquisition of st jude medical into the medical device segment and alere inc alere into the diagnostic product segment in order to leverage economy of scale and reduce cost of december the accrued balance associated with these action wa million from to abbott recorded employee related severance and other charge totaling approximately million comprised of million in million in and million in approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense over the last three year of december the accrued liability remaining in the consolidated balance sheet related to these action total million from to abbott management approved plan to streamline operation in order to reduce cost and improve efficiency in various abbott business including the nutritional established pharmaceutical and vascular business of december the accrued balance associated with these action wa million from to abbott recorded employee related severance and other charge totaling approximately million comprised of million in and million in approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense over the two year of december the accrued liability remaining in the consolidated balance sheet related to these action total million in abbott management approved plan to streamline operation in order to reduce cost and improve efficiency in various abbott business including the diagnostics established pharmaceutical nutritional and medical device business abbott recorded employee related severance and other charge of approximately million approximately million wa recorded in cost of product sold approximately million wa recorded in research and development and approximately million wa recorded in selling general and administrative expense abbott laboratory and subsidiariesnotes to consolidated financial statement continued note restructuring plan continued the following summarizes the activity for these restructurings in million restructuring charge in and other adjustment accrued balance at december note incentive stock programthe incentive stock program authorizes the granting of nonqualified stock option restricted stock award restricted stock unit performance award foreign benefit and other share based award stock option and restricted stock award and unit comprise the majority of benefit that have been granted and are currently outstanding under this program and prior program in abbott granted stock option restricted stock award and restricted stock unit under this program under abbott stock incentive program the purchase price of share under option must be at least equal to the fair market value of the common stock on the date of grant and the maximum term of an option is year option generally vest equally over three year restricted stock award generally vest over three year with no more than one third of the award vesting in any one year upon abbott reaching minimum return on equity target restricted stock unit vest over three year and upon vesting the recipient receives one share of abbott stock for each vested restricted stock unit the aggregate fair market value of option and restricted stock award and unit is recognized expense over the requisite service period which may be shorter than the vesting period if an employee is retirement eligible forfeiture are estimated at the time of grant restricted stock award and settlement of vested restricted stock unit are issued out of treasury share abbott generally issue new share for exercise of stock option policy abbott doe not purchase it share relating to it share based program in april abbott shareholder authorized the incentive stock program under which maximum of million share were available for issuance at december approximately million share remained available for future issuance the following table summarizes stock option activity for the year ended december and the outstanding stock option of december weighted weighted average average remaining aggregate intrinsic value in million option exercise price life year intrinsic valueoutstanding at december exercised lapsed outstanding at december at december abbott laboratory and subsidiariesnotes to consolidated financial statement continued note incentive stock program continued the following table summarizes restricted stock award and unit activity for the year ended december weighted average grant date share unit fair valueoutstanding at december at december the fair market value of restricted stock award and unit vested in and wa million million and million respectively the total intrinsic value of option exercised in and wa million million and million respectively the total unrecognized compensation cost related to all share based compensation plan at december amounted to approximately million which is expected to be recognized over the next three year total non cash stock compensation expense charged against income from continuing operation in and for share based plan totaled approximately million million and million respectively and the tax benefit recognized wa approximately million million and million respectively stock compensation cost capitalized part of inventory is not significant the table below summarizes the fair value of an option granted in and and the assumption included in the black scholes option pricing model used to estimate the fair value fair value risk free interest rate average life of option year volatility dividend yield the risk free interest rate is based on the rate available at the time of the grant for zero coupon government issue with remaining term equal to the option expected life the average life of an option is based on both historical and projected exercise and lapsing data expected volatility is based on implied volatility from traded option on abbott stock and historical volatility of abbott stock over the expected life of the option dividend yield is based on the option exercise price and annual dividend rate at the time of grant abbott laboratory and subsidiariesnotes to consolidated financial statement continued note debt and line of credit the following is summary of long term debt at december in million note due note due note due year term loan due note due note due note due note due note due note due note due note due note due note due note due note due note due note due debt issuance cost other including fair value adjustment relating to interest rate hedge contract designated fair value hedge carrying amount of long term debt current portion long term portion on june abbott completed the issuance of billion aggregate principal amount of senior note consisting of million of it note due and million of it note due on september abbott repaid the billion outstanding principal amount of it note due upon maturity the repayment equated to approximately billion abbott ha readily available financial resource including unused line of credit that support commercial paper borrowing arrangement and provide abbott with the ability to borrow up to billion on an unsecured basis the line of credit are part of five year credit agreement revolving credit agreement that abbott entered into on november at that time abbott also terminated it revolving credit agreement there were no outstanding borrowing under the revolving credit agreement at the time of it termination any borrowing under the revolving credit agreement will mature and be payable on november any borrowing under the revolving credit agreement will bear interest at abbott option based on either base rate or eurodollar rate plus an applicable margin based on abbott credit rating in abbott long term borrowing and debt issuance included the following on november abbott wholly owned subsidiary abbott ireland financing dac completed an offering of billion of long term debt consisting of million of note due and million of note due the proceeds equated to approximately billion the note are guaranteed by abbott on november abbott borrowed billion under year term loan and designated the yen denominated loan hedge of it net investment in certain foreign subsidiary the term loan bear interest at tibor plus fixed spread and the interest rate is reset quarterly the proceeds equated to approximately million abbott laboratory and subsidiariesnotes to consolidated financial statement continued note debt and line of credit continued in abbott repayment of long term debt included the following billion outstanding principal amount of it note due redeemed on february billion principal amount of it note due redeemed on december abbott incurred charge of million related to the early repayment of this debt the note were redeemed under bond redemption authorization approved by the board of director in the note were redeemed under bond redemption authorization approved by the board of director in september for the early redemption of up to billion of outstanding long term note the bond redemption authorization superseded the board authorization of the billion authorization billion remains available of december principal payment required on long term debt outstanding at december are million in billion in billion in billion in billion in and billion in and thereafter at december abbott long term debt rating wa by standard poor corporation and by moody in december abbott repaid short term facility for approximately million after the repayment abbott ha no short term borrowing abbott weighted average interest rate on short term borrowing wa at december and note leasesleases where abbott is the lesseeabbott ha entered into operating lease the lessee for office space manufacturing facility laboratory warehouse vehicle and equipment finance lease are not significant abbott operating lease generally have remaining lease term of to year some lease include option to extend beyond the original lease term generally up to year and some include option to terminate early these option have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised for all of it asset class abbott elected the practical expedient allowed under fasb asc no lease to account for each lease component the right to use office space and the associated non lease component maintenance service single lease component abbott also elected the short term lease accounting policy for all asset class therefore abbott is not recognizing lease liability or right of use rou asset for any lease that at the commencement date ha lease term of month or le and doe not include an option to purchase the underlying asset that abbott is reasonably certain to exercise abbott lease typically do not provide an implicit rate the interest rate used to determine the present value of the payment under each lease typically reflects abbott incremental borrowing rate based on information available at the lease commencement date abbott incremental borrowing rate at january were used for operating lease that commenced prior to january when asc no wa adopted abbott laboratory and subsidiariesnotes to consolidated financial statement continued note lease continued the following table provides information related to abbott operating lease in million except weighted average operating lease cost cash paid for amount included in the measurement of operating lease liability rou asset arising from entering into new operating lease obligation weighted average remaining lease term at december in year weighted average discount rate at december includes short term lease expense and variable lease cost which were immaterial in the year ended december and future minimum lease payment under non cancellable operating lease of december were follows in million future minimum lease payment undiscounted imputed interest present value of lease liability the following table summarizes the amount and location of operating lease rou asset and lease liability in million december december balance sheet caption operating lease rou asset deferred income tax and other asset operating lease liability current other accrued liabilitiesnon current post employment obligation and other long term liabilitiestotal liability abbott laboratory and subsidiariesnotes to consolidated financial statement continued note lease continued lease where abbott is the lessorcertain asset primarily diagnostics instrument are leased to customer under contractual arrangement that typically include an operating or sale type lease well performance obligation for reagent and other consumables sale type lease are not significant contract term vary by customer and may include option to terminate the contract or option to extend the contract where instrument are provided under operating lease arrangement some portion or the entire lease revenue may be variable and subject to subsequent non lease component reagent sale the allocation of revenue between the lease and non lease component is based on standalone selling price operating lease revenue represented le than percent of abbott total net sale in the year ended december and asset related to operating lease are reported within net property and equipment on the consolidated balance sheet the original cost and the net book value of such asset were billion and billion respectively of december and billion and billion respectively of december note financial instrument derivative and fair value measurescertain abbott foreign subsidiary enter into foreign currency forward exchange contract to manage exposure to change in foreign exchange rate primarily for anticipated intercompany purchase by those subsidiary whose functional currency are not the dollar these contract with gross notional amount totaling billion at december and billion at december are designated cash flow hedge of the variability of the cash flow due to change in foreign exchange rate and are recorded at fair value accumulated gain and loss of december will be included in cost of product sold at the time the product are sold generally through the next twelve to eighteen month abbott enters into foreign currency forward exchange contract to manage currency exposure for foreign currency denominated third party trade payable and receivables and for intercompany loan and trade account payable where the receivable or payable is denominated in currency other than the functional currency of the entity for intercompany loan the contract require abbott to sell or buy foreign currency primarily european currency in exchange for primarily dollar and european currency for intercompany and trade payable and receivables the currency exposure are primarily the dollar and european currency at december and abbott held gross notional amount of billion and billion respectively of such foreign currency forward exchange contract in november abbott borrowed billion under year term loan and designated the yen denominated loan hedge of the net investment in certain foreign subsidiary the proceeds equated to approximately million the value of this long term debt wa approximately million and million of december and december respectively the change in the value of the debt which is due to change in foreign exchange rate wa recorded in accumulated other comprehensive income loss net of tax abbott laboratory and subsidiariesnotes to consolidated financial statement continued note financial instrument derivative and fair value measure continued abbott is party to interest rate hedge contract totaling approximately billion at december and to manage it exposure to change in the fair value of fixed rate debt these contract are designated fair value hedge of the variability of the fair value of fixed rate debt due to change in the long term benchmark interest rate the effect of the hedge is to change fixed rate interest obligation to variable rate for that portion of the debt abbott record the contract at fair value and adjusts the carrying amount of the fixed rate debt by an offsetting amount the following table summarizes the amount and location of certain derivative financial instrument of december fair value asset fair value liability in million balance sheet caption balance sheet captioninterest rate swap designated fair value hedge deferred income tax and other asset post employment obligation and other long term liabilitiesforeign currency forward exchange contract hedging instrument other prepaid expense and receivables other accrued liabilitiesothers not designated hedge other prepaid expense and receivables other accrued liabilitiesdebt designated hedge of net investment in foreign subsidiary long term debt the following table summarizes the activity for foreign currency forward exchange contract designated cash flow hedge debt designated hedge of net investment in foreign subsidiary and certain other derivative financial instrument well the amount and location of income expense and gain loss reclassified into income gain loss recognized in income expense and other comprehensive gain loss reclassified income loss into income in million income statement captionforeign currency forward exchange contract designated cash flow hedge cost of product solddebt designated hedge of net investment in foreign subsidiary ainterest rate swap designated fair value hedge interest expense gain of million loss of million and gain of million were recognized in and respectively related to foreign currency forward exchange contract not designated hedge these amount are reported in the consolidated statement of earnings on the net foreign exchange gain loss line the interest rate swap are designated fair value hedge of the variability of the fair value of fixed rate debt due to change in the long term benchmark interest rate the hedged debt is marked to market offsetting the effect of marking the interest rate swap to market abbott laboratory and subsidiariesnotes to consolidated financial statement continued note financial instrument derivative and fair value measure continued the carrying value and fair value of certain financial instrument of december are shown in the table below the carrying value of all other financial instrument approximate their estimated fair value the counterparties to financial instrument consist of select major international financial institution abbott doe not expect any loss from nonperformance by these counterparties carrying fair carrying fair in million value value value valuelong term investment security equity security long term debt foreign currency forward exchange contract receivable position payable position interest rate hedge contract receivable position payable position the fair value of the debt wa determined based on significant other observable input including current interest rate the following table summarizes the base used to measure certain asset and liability at fair value on recurring basis in the balance sheet basis of fair value measurement quoted significant price in other significant outstanding active observable unobservable in million balance market input inputsdecember equity security interest rate swap derivative financial instrument foreign currency forward exchange contract total asset fair value of hedged long term debt foreign currency forward exchange contract contingent consideration related to business combination liability december equity security interest rate swap derivative financial instrument foreign currency forward exchange contract total asset fair value of hedged long term debt foreign currency forward exchange contract contingent consideration related to business combination liability abbott laboratory and subsidiariesnotes to consolidated financial statement continued note financial instrument derivative and fair value measure continued the fair value of foreign currency forward exchange contract is determined using market approach which utilizes value for comparable derivative instrument the fair value of the debt wa determined based on the face value of the debt adjusted for the fair value of the interest rate swap which is based on discounted cash flow analysis using significant other observable input contingent consideration relates to business acquired by abbott the increase in contingent consideration during the year primarily reflects the fair value of the contingent consideration that resulted from recent acquisition the fair value of such contingent consideration wa determined based on an independent appraisal the maximum amount for certain contingent consideration is not determinable it is based on percent of certain sale excluding such contingent consideration the maximum amount that may be due under the other contingent consideration arrangement wa estimated at december to be approximately million which is dependent upon attaining certain sale threshold or upon the occurrence of certain event such regulatory approval the increase from the estimate at december of approximately million reflects the additional contingent consideration that resulted from recent acquisition partially offset by the expiration of certain contingent consideration arrangement note litigation and environmental mattersabbott ha been identified potentially responsible party for investigation and cleanup cost at number of location in the united state and puerto rico under federal and state remediation law and is investigating potential contamination at number of company owned location abbott ha recorded an estimated cleanup cost for each site for which management belief abbott ha probable loss exposure no individual site cleanup exposure is expected to exceed million and the aggregate cleanup exposure is not expected to exceed million abbott is involved in various claim and legal proceeding and abbott estimate the range of possible loss for it legal proceeding and environmental exposure to be from approximately million to million the recorded accrual balance at december for these proceeding and exposure wa approximately million this accrual represents management best estimate of probable loss defined by fasb asc no contingency within the next year legal proceeding may occur that may result in change in the estimated loss accrued by abbott while it is not feasible to predict the outcome of all such proceeding and exposure with certainty management belief that their ultimate disposition should not have material adverse effect on abbott financial position cash flow or result of operation abbott laboratory and subsidiariesnotes to consolidated financial statement continued note post employment benefitsretirement plan consist of defined benefit defined contribution and medical and dental plan information for abbott major defined benefit plan and post employment medical and dental benefit plan is follows medical and dental defined benefit plan plan in million benefit obligation january cost benefit earned during the year cost on projected benefit obligation gain loss primarily change in discount rate plan design change law change and difference between actual and estimated health care cost benefit paid other including foreign currency translation benefit obligation december asset at fair value january return loss on plan asset contribution paid other including foreign currency translation plan asset at fair value december benefit obligation le greater than plan asset december long term asset short term liability long term liability net asset liability amount recognized in accumulated other comprehensive income loss actuarial loss net service cost credit total the million of defined benefit plan gain in that decreased the projected benefit obligation primarily reflect the year over year increase in the discount rate used to measure the obligation the billion of defined benefit plan loss in that increased the projected benefit obligation primarily reflect the year over year decline in the discount rate used to measure the obligation the projected benefit obligation for non defined benefit plan were billion and billion at december and respectively the accumulated benefit obligation for all defined benefit plan were billion and billion at december and respectively for plan where the projected benefit obligation exceeded plan asset at december and the projected benefit obligation and the aggregate plan asset were follows in million benefit obligation value of plan asset abbott laboratory and subsidiariesnotes to consolidated financial statement continued note post employment benefit continued for plan where the accumulated benefit obligation exceeded plan asset at december and the aggregate accumulated benefit obligation the projected benefit obligation and the aggregate plan asset were follows in million benefit obligation benefit obligation value of plan asset the component of the net periodic benefit cost were follows medical and defined benefit plan dental plan in million cost benefit earned during the year cost on projected benefit obligation return on plan asset amortization of actuarial loss of prior service cost credit total net cost other comprehensive income loss for each respective year includes the amortization of actuarial loss and prior service cost credit noted in the previous table other comprehensive income loss for each respective year also includes net actuarial gain of billion for defined benefit plan and gain of million for medical and dental plan in net actuarial loss of million for defined benefit plan and gain of million for medical and dental plan in and net actuarial loss of million for defined benefit plan and loss of million for medical and dental plan in the net actuarial gain in are primarily due to the favorable impact of actual asset return in excess of expected return and the year over year increase in discount rate the net actuarial loss in are primarily due to the year over year decline in discount rate partially offset by the impact of actual asset return in excess of expected return the weighted average assumption used to determine benefit obligation for defined benefit plan and medical and dental plan are follows discount rate expected aggregate average long term change in compensation the weighted average assumption used to determine the net cost for defined benefit plan and medical and dental plan are follows discount rate expected return on plan asset expected aggregate average long term change in compensation the assumed health care cost trend rate for medical and dental plan at december were follows health care cost trend rate assumed for the next year rate that the cost trend rate gradually decline to year that rate reach the assumed ultimate rate abbott laboratory and subsidiariesnotes to consolidated financial statement continued note post employment benefit continued the discount rate used to measure liability were determined based on high quality fixed income security that match the duration of the expected retiree benefit the health care cost trend rate represent abbott expected annual rate of change in the cost of health care benefit and are forward projection of health care cost of the measurement date the following table summarizes the base used to measure the defined benefit and medical and dental plan asset at fair value basis of fair value measurement quoted significant price in other significant outstanding active observable unobservable measured at in million balance market input input nav december equity large cap mid and small cap income security government security debt instrument government security return fund and cash equivalent equity large cap mid and small cap income security government security debt instrument government security return fund and cash equivalent mix of index fund and actively managed equity account that are benchmarked to various large cap index mix of index fund and actively managed equity account that are benchmarked to various mid and small cap index mix of index fund and actively managed pooled investment fund that are benchmarked to various non equity index in both developed and emerging market mix of index fund and actively managed account that are benchmarked to various government bond index mix of index fund and actively managed account that are benchmarked to various corporate bond index primarily united kingdom canada japan and eurozone government bond abbott laboratory and subsidiariesnotes to consolidated financial statement continued note post employment benefit continued primarily asset backed security bank loan and actively managed diversified fixed income vehicle benchmarked to libor primarily hedge fund and fund invested by manager that have global mandate with the flexibility to allocate capital broadly across wide range of asset class and strategy including but not limited to equity fixed income commodity interest rate future currency and other security to outperform an agreed upon benchmark with specific return and volatility target primarily investment in private fund such private equity private credit private real estate and private energy fund investment measured at fair value using the net asset value nav practical expedient have not been classified in the fair value hierarchy the fair value amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the amount presented in the consolidated balance sheet equity that are valued using quoted price are valued at the published market price equity in common collective trust or registered investment company are valued at the nav provided by the fund administrator the nav is based on the value of the underlying asset owned by the fund minus it liability for approximately half of these fund investment may be redeemed once per week or month with required to day notice period for the remaining fund daily redemption of an investment is allowed fixed income security that are valued using significant other observable input are valued at price obtained from independent financial service industry recognized vendor abbott did not have any unfunded commitment related to fixed income fund at december and fixed income security in common collective trust or registered investment company are valued at the nav provided by the fund administrator for the majority of these fund investment may be redeemed either weekly or monthly with required to day notice period for the remaining fund investment may be generally redeemed daily absolute return fund are valued at the nav provided by the fund administrator all private fund are valued at the nav provided by the fund on one quarter lag adjusted for known cash flow and significant event through the reporting date abbott did not have any unfunded commitment related to absolute return fund at december and investment in these fund may be generally redeemed monthly or quarterly with required notice period ranging from to day for approximately million and million of the absolute return fund redemption are subject to percent gate and percent gate respectively and million is subject to lock until investment in the private fund can not be redeemed but the fund will make distribution through liquidation the estimate of the liquidation period for each fund range from to abbott unfunded commitment in these fund wa million and million of december and respectively the investment mix of equity security fixed income and other asset allocation strategy is based upon achieving desired return well balancing higher return more volatile equity security with lower return le volatile fixed income security investment allocation are made across range of market industry sector capitalization size and in the case of fixed income security maturity and credit quality the plan do not directly hold any security of abbott there are no known significant concentration of risk in the plan asset abbott medical and dental plan asset are invested in similar mix the pension plan asset the actual asset allocation percentage at year end are consistent with the company targeted asset allocation percentage the plan expected return on asset shown above is based on management expectation of long term average rate of return to be achieved by the underlying investment portfolio in establishing this assumption management considers historical and expected return for the asset class in which the plan are invested well current economic and capital market condition abbott fund it domestic pension plan according to irs funding limitation international pension plan are funded according to similar regulation abbott funded million in and million in to defined pension plan abbott expects to contribute approximately million to it pension plan in abbott laboratory and subsidiariesnotes to consolidated financial statement continued note post employment benefit continued total benefit payment expected to be paid to participant which includes payment funded from company asset well paid from the plan are follows defined medical and in million benefit plan dental to the abbott stock retirement plan is the principal defined contribution plan abbott contribution to this plan were million in million in and million in note tax on earnings from continuing operation tax on earnings from continuing operation reflect the annual effective rate including charge for interest and penalty deferred income tax reflect the tax consequence on future year of difference between the tax base of asset and liability and their financial reporting amount in tax on earnings from continuing operation include approximately million in excess tax benefit associated with share based compensation and approximately million of net tax benefit result of the resolution of various tax position related to prior year in tax on earnings from continuing operation include the recognition of approximately million of tax benefit associated with the impairment of certain asset approximately million of net tax benefit result of the resolution of various tax position related to prior year and approximately million in excess tax benefit associated with share based compensation in tax on earnings from continuing operation also include million increase to the transition tax liability associated with the tcja the million increase to the transition tax liability wa the result of the resolution of various tax position related to prior year this adjustment increased the cumulative net tax expense related to the tcja to billion the one time transition tax is based on abbott total post earnings and profit that were previously deferred from income tax the tax computation also requires the determination of the amount of post considered held in cash and other specified asset of december the remaining balance of abbott transition tax obligation is approximately million which will be paid over the next five year allowed by the tcja earnings from discontinued operation net of tax in reflect the recognition of million of net tax benefit primarily result of the resolution of various tax position related to prior year in tax on earnings from continuing operation included approximately million in excess tax benefit associated with share based compensation an million reduction of the transition tax and million of tax expense resulting from tax legislation enacted in the fourth quarter of in india the million reduction to the transition tax liability wa the result of the issuance of final transition tax regulation by the department of treasury in undistributed foreign earnings remain indefinitely reinvested in foreign operation determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in it foreign entity is not practicable in the abbott federal income tax return through are settled there are numerous other income tax jurisdiction for which tax return are not yet settled none of which are individually significant reserve for interest and penalty are not significant abbott laboratory and subsidiariesnotes to consolidated financial statement continued note tax on earnings from continuing operation continued earnings from continuing operation before tax and the related provision for tax on earnings from continuing operation were follows in million from continuing operation before tax domestic in million on earnings from continuing operation current domestic current domestic foreign total deferred total difference between the effective income tax rate and the statutory tax rate were follows statutory tax rate on earnings from continuing operation impact of foreign operation impact of tcja and other related item foreign derived intangible income benefit domestic impairment loss excess tax benefit related to stock compensation research tax credit resolution of certain tax position pertaining to prior year intercompany restructurings and integration state tax net of federal benefit all other net effective tax rate on earnings from continuing operation impact of foreign operation is primarily derived from operation in puerto rico switzerland ireland the netherlands costa rica singapore and malta abbott laboratory and subsidiariesnotes to consolidated financial statement continued note tax on earnings from continuing operation continued the tax effect of the difference that give rise to deferred tax asset and liability were follows in million tax asset compensation and employee benefit primarily reserve not currently deductible and nol and credit carryforwards receivable reserve reserve liability intercompany profit deferred tax asset before valuation allowance allowance total deferred tax asset tax liability depreciation right of use lease asset other primarily the excess of book basis over tax basis of intangible asset total deferred tax liability total net deferred tax asset liability abbott ha incurred loss in foreign jurisdiction where realization of the future economic benefit is remote that the benefit is not reflected deferred tax asset the following table summarizes the gross amount of unrecognized tax benefit without regard to reduction in tax liability or addition to deferred tax asset and liability if such unrecognized tax benefit were settled in million due to current year tax position due to prior year tax position due to prior year tax position settlement lapse of statute december the increase due to prior year tax position includes approximately million of international tax position for which deferred tax asset ha not been recorded because recognition of the future benefit is not expected the total amount of unrecognized tax benefit that if recognized would impact the effective tax rate is approximately billion abbott belief that it is reasonably possible that the recorded amount of gross unrecognized tax benefit may decrease within range of million to million including cash adjustment within the next twelve month result of concluding various domestic and international tax matter abbott laboratory and subsidiariesnotes to consolidated financial statement continued note segment and geographic area informationabbott principal business is the discovery development manufacture and sale of broad line of health care product abbott product are generally sold directly to retailer wholesaler hospital health care facility laboratory physician office and government agency throughout the world abbott reportable segment are follows established pharmaceutical product international sale of broad line of branded generic pharmaceutical product nutritional product worldwide sale of broad line of adult and pediatric nutritional product diagnostic product worldwide sale of diagnostic system and test for blood bank hospital commercial laboratory and alternate care testing site for segment reporting purpose the core laboratory diagnostics rapid diagnostics molecular diagnostics and point of care division are aggregated and reported the diagnostic product segment medical device worldwide sale of rhythm management electrophysiology heart failure vascular structural heart neuromodulation and diabetes care product for segment reporting purpose the cardiac rhythm management electrophysiology and heart failure vascular neuromodulation structural heart and diabetes care division are aggregated and reported the medical device segment abbott underlying accounting record are maintained on legal entity basis for government and public reporting requirement segment disclosure are on performance basis consistent with internal management reporting the cost of some corporate function and the cost of certain employee benefit are charged to segment at predetermined rate that approximate cost remaining cost if any are not allocated to segment in addition intangible asset amortization is not allocated to operating segment and intangible asset and goodwill are not included in the measure of each segment asset the following segment information ha been prepared in accordance with the internal accounting policy of abbott described above and are not presented in accordance with generally accepted accounting principle applied to the consolidated financial statement net sale to external customer operating earnings in million pharmaceutical product product product device reportable segment total in the impact of foreign exchange favorably impacted net sale and unfavorably impacted operating earnings in and the impact of foreign exchange unfavorably impacted net sale and operating earnings abbott laboratory and subsidiariesnotes to consolidated financial statement continued note segment and geographic area information continued in million reportable segment operating earnings function and benefit plan cost net interest expense loss on extinguishment of debt share based compensation amortization of intangible asset other net earnings from continuing operation before tax other net includes integration cost associated with the acquisition of st jude medical and alere and restructuring charge in and restructuring charge include abbott restructuring plan for it covid test manufacturing network other net for also includes cost related to certain litigation other net in also includes cost related to asset impairment partially offset by income from the settlement of litigation charge for restructuring action and other cost reduction initiative were approximately million in million in and million in addition to depreciation property and equipment total asset in million pharmaceutical device reportable segment total in million reportable segment asset and investment and intangible asset other asset all other includes the long term asset associated with the defined benefit plan of billion in and million in abbott laboratory and subsidiariesnotes to consolidated financial statement continued note segment and geographic area information continued net sale to external customer in million state other country sale by country are based on the country that sold the product long lived asset on geographic basis primarily include property and equipment it excludes goodwill intangible asset deferred tax asset and financial instrument at december and long lived asset totaled billion and billion respectively and in the united state such asset totaled billion and billion respectively long lived asset balance associated with other country were not material on an individual country basis in either of the two year management report on internal control over financial reportingthe management of abbott laboratory is responsible for establishing and maintaining adequate internal control over financial reporting abbott internal control system wa designed to provide reasonable assurance to the company management and board of director regarding the preparation and fair presentation of published financial statement all internal control system no matter how well designed have inherent limitation therefore even those system determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation abbott management assessed the effectiveness of the company internal control over financial reporting of december in making this assessment it used the criterion set forth in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission based on our assessment believe that of december the company internal control over financial reporting wa effective based on those criterion abbott independent registered public accounting firm ha issued an audit report on their assessment of the effectiveness of the company internal control over financial reporting this report appears on page robert fordchairman of the board and chief executive officerrobert funck jr executive vice president finance and chief financial officerphilip boudreauvice president finance and controllerfebruary report of independent registered public accounting firmto the shareholder and board of director of abbott laboratoriesopinion on the financial statementswe have audited the accompanying consolidated balance sheet of abbott laboratory and subsidiary the company of december and the related consolidated statement of earnings comprehensive income shareholder investment and cash flow for each of the three year in the period ended december and the related note collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinionthese financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit matterthe critical audit matter communicated below is matter arising from the current period audit of the financial statement that wa communicated or required to be communicated to the audit committee and that relates to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of the critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which it relates income tax unrecognized tax benefitsdescription of thematter described in note to the consolidated financial statement unrecognized tax benefit were approximately billion at december unrecognized tax benefit are assessed by management quarterly for identification and measurement or more frequently if there are any indicator suggesting change in unrecognized tax benefit assessing tax position involves judgement including interpreting tax law of multiple jurisdiction and assumption relevant to the measurement of an unrecognized tax benefit including the estimated amount of tax liability that may be incurred should the tax position not be sustained upon inspection by tax authority these judgement and assumption can significantly affect unrecognized tax benefit how we addressedthe matter in ouraudit we obtained an understanding evaluated the design and tested the operating effectiveness of control over the company identification and measurement of unrecognized tax benefit well it process for the assessment of event that may indicate change in unrecognized tax benefit is warranted for example we tested control over management review of the completeness of identified unrecognized tax benefit well control over management review of significant assumption used within the measurement of unrecognized tax benefit with the support of our tax professional among other audit procedure performed we evaluated the reasonableness of management judgement with respect to the interpretation of tax law of multiple jurisdiction by reading and evaluating management documentation including relevant accounting policy and by considering how tax law including statute regulation and case law affected management judgment we tested the completeness of management assessment of the identification of unrecognized tax benefit and possible outcome related to it including evaluation of technical merit of the unrecognized tax benefit we also tested with the support of our valuation specialist appropriateness and consistency of management method and significant assumption associated with the measurement of unrecognized tax benefit including assessing the estimated amount of tax liability that may be incurred should the tax position not be sustained upon inspection by tax authority ernst young llpwe have served the company auditor since chicago illinoisfebruary report of independent registered public accounting firmto the shareholder and board of director of abbott laboratoriesopinion on internal control over financial reportingwe have audited abbott laboratory and subsidiary internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion abbott laboratory and subsidiary the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of earnings comprehensive income shareholder investment and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpchicago illinoisfebruary item change in and disagreement with accountant on accounting and financial disclosurenone item control and proceduresdisclosure control and proceduresevaluation of disclosure control and procedure the chief executive officer robert ford and the chief financial officer robert funck jr evaluated the effectiveness of abbott laboratory disclosure control and procedure of the end of the period covered by this report and concluded that abbott laboratory disclosure control and procedure were effective to ensure that information abbott is required to disclose in the report that it file or submits with the commission under the security exchange act of the exchange act is recorded processed summarized and reported within the time period specified in the commission rule and form and to ensure that information required to be disclosed by abbott in the report that it file or submits under the exchange act is accumulated and communicated to abbott management including it principal executive officer and principal financial officer appropriate to allow timely decision regarding required disclosure internal control over financial reportingmanagement annual report on internal control over financial reporting management report on abbott internal control over financial reporting is included on page hereof the report of abbott independent registered public accounting firm related to their assessment of the effectiveness of internal control over financial reporting is included on page hereof change in internal control over financial reporting during the quarter ended december there were no change in abbott internal control over financial reporting defined in rule under the exchange act that have materially affected or are reasonably likely to materially affect abbott internal control over financial reporting item other informationnone item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable part iiiitem director executive officer and corporate governanceincorporated herein by reference are nominee for election director committee of the board of director and procedure for recommendation and nomination of director and transaction of business at annual meeting to be included in the abbott laboratory proxy statement the proxy statement will be filed on or about march also incorporated herein by reference is the text found under the caption information about our executive officer on page through hereof abbott ha adopted code of ethic that applies to it principal executive officer principal financial officer and principal accounting officer and controller that code is part of abbott code of business conduct which is available free of charge through abbott investor relation website www abbottinvestor com abbott intends to include on it website any amendment to or waiver from provision of it code of ethic that applies to abbott principal executive officer principal financial officer and principal accounting officer and controller that relates to any element of the code of ethic definition enumerated in item of regulation item executive compensationthe material to be included in the proxy statement under the heading director compensation and executive compensation is incorporated herein by reference the proxy statement will be filed on or about march item security ownership of certain beneficial owner and management and related stockholder matter equity compensation plan information the following table present information of december about our compensation plan under which abbott common share have been authorized for issuance number of security remaining number of available for security to be future issuance issued upon weighted average under equity exercise of exercise price compensation outstanding of outstanding plan excluding option warrant option warrant security reflectedplan category and right and right in column equity compensation plan approved by security holder compensation plan not approved by security holder abbott laboratory incentive stock program benefit under the abbott laboratory incentive stock program the program include non qualified stock option restricted stock restricted stock unit performance award other share based award including stock appreciation right dividend equivalent and recognition award award to non employee director and foreign benefit the share that remain available for issuance under the program may be issued in connection with any one of these benefit and may be either authorized but unissued share or treasury share except that restricted stock award are satisfied from treasury share if there is lapse expiration termination forfeiture or cancellation of any benefit granted under the program without the issuance of share or payment of cash thereunder the share subject to or reserved for that benefit or so reacquired may be used for new stock option right or award of any type authorized under the abbott laboratory incentive stock program the program if share are issued under any benefit under the program and thereafter are reacquired by abbott pursuant to right reserved upon their issuance or pursuant to the payment of the purchase price of share under stock option by delivery of other common share of abbott the share subject to or reserved for that benefit or so reacquired may not again be used for new stock option right or award of any type authorized under the program in april the program wa replaced by the program no further award will be granted under the program ii abbott laboratory incentive stock program benefit under the program include non qualified stock option restricted stock restricted stock unit performance award other share based award including stock appreciation right dividend equivalent and recognition award award to non employee director and foreign benefit the share that remain available for issuance under the program may be issued in connection with any one of these benefit and may be either authorized but unissued share or treasury share except that restricted stock award are satisfied from treasury share if there is lapse expiration termination forfeiture or cancellation of any benefit granted under the program without the issuance of share or payment of cash thereunder the share subject to or reserved for that benefit or so reacquired may again be used for new stock option right or award of any type authorized under the program if share are issued under any benefit under the program and thereafter are reacquired by abbott pursuant to right reserved upon their issuance or pursuant to the payment of the purchase price of share under stock option by delivery of other common share of abbott the share subject to or reserved for that benefit or so reacquired may not again be used for new stock option right or award of any type authorized under the program iii abbott laboratory employee stock purchase plan for non employee eligible employee of participating non affiliate of abbott may participate in this plan an eligible employee may authorize payroll deduction at the rate of to of eligible compensation in multiple of one percent subject to limit of during any purchase cycle purchase cycle are generally six month long and usually begin on august and february on the last day of each purchase cycle abbott us participant contribution to acquire abbott common share the share may be either authorized but unissued share treasury share or share acquired on the open market the purchase price is typically of the lower of the fair market value of the share on the purchase date or on the first day of that purchase cycle the number of share subject to outstanding option is indeterminable column and of the above table do not include information on the employee stock purchase plan of december an aggregate of common share were available for future issuance under the employee stock purchase plan including share subject to purchase during the current purchase cycle in april the employee stock purchase plan for non employee wa amended and restated the abbott laboratory employee stock purchase plan for non employee not included in the table st jude medical inc plan in in connection with the acquisition of st jude medical inc option outstanding under the st jude medical inc stock incentive plan amended and restated were assumed by abbott and converted into abbott option of substantially equivalent value of december option remained outstanding under these plan these option have weighted average purchase price of no further award will be granted under these plan for additional information concerning the abbott laboratory incentive stock program the abbott laboratory incentive stock program and the abbott laboratory employee stock purchase plan for non employee see the discussion in note entitled incentive stock program of the note to consolidated financial statement included under item financial statement and supplementary data information concerning security ownership incorporated herein by reference is the material under the heading security ownership of executive officer and director and information concerning security ownership in the proxy statement the proxy statement will be filed on or about march item certain relationship and related transaction and director independencethe material to be included in the proxy statement under the heading the board of director committee of the board of director and approval process for related person transaction is incorporated herein by reference the proxy statement will be filed on or about march item principal accounting fee and servicesthe material to be included in the proxy statement under the heading audit fee and non audit fee and policy on audit committee pre approval of audit and permissible non audit service of the independent auditor is incorporated herein by reference the proxy statement will be filed on or about march part ivitem exhibit financial statement schedule document filed part of this form financial statement see item financial statement and supplementary data on page hereof for list of financial statement financial statement schedule the required financial statement schedule are found on the page indicated below these schedule should be read in conjunction with the consolidated financial statement of abbott laboratory abbott laboratory financial statement schedule page no valuation and qualifying account schedule ii iii iv and are not submitted because they are not applicable or not required report of independent registered public accounting firm financial statement of business acquired by the registrant have been omitted pursuant to rule of regulation exhibit required by item of regulation the information called for by this paragraph is set forth in item below exhibit filed kexhibittableitem no amended and restated article of incorporation of abbott laboratory filed exhibit to the abbott laboratory current report on form filed on april by law of abbott laboratory amended and restated effective december filed exhibit to the abbott laboratory current report on form filed on december indenture dated of february between abbott laboratory and the bank of new york mellon trust company successor to morgan trust company national association successor to bank one trust company including form of security filed exhibit to the abbott laboratory registration statement on form dated february supplemental indenture dated of february between abbott laboratory and the bank of new york mellon trust company successor to morgan trust company national association filed exhibit to the abbott laboratory registration statement on form dated february form of note due filed exhibit to the abbott laboratory current report on form dated november action of the authorized officer with respect to abbott note due note due and note due filed exhibit to the abbott laboratory current report on form dated november form of note due filed exhibit to the abbott laboratory current report on form dated february action of the authorized officer with respect to abbott note due and note due filed exhibit to the abbott laboratory current report on form dated february form of note filed exhibit to the abbott laboratory current report on form dated may kexhibittableitem no action of the authorized officer with respect to abbott note note and note filed exhibit to the abbott laboratory current report on form dated may indenture dated of march between abbott laboratory and bank national association including form of security filed exhibit to the abbott laboratory current report on form dated march form of note due filed exhibit to the abbott laboratory current report on form dated march form of note due filed exhibit to the abbott laboratory current report on form dated march action of the authorized officer with respect to abbott note note and note filed exhibit to the abbott laboratory current report on form dated march form of note due filed exhibit to the abbott laboratory current report on form dated november form of note due filed exhibit to the abbott laboratory current report on form dated november form of note due filed exhibit to the abbott laboratory current report on form dated november form of note due filed exhibit to the abbott laboratory current report on form dated november officer certificate pursuant to section and of the indenture with respect to note due note due note due note due note due and note due including form of note filed exhibit to the abbott laboratory annual report on form form of note due filed exhibit to the abbott laboratory current report on form dated march form of note due filed exhibit to the abbott laboratory current report on form dated march officer certificate pursuant to section and of the indenture with respect to note due note due note due note due and note due including form of note filed exhibit to the abbott laboratory quarterly report on form for the period ended march indenture dated of july between st jude medical llc successor to st jude medical inc and bank national association trustee filed exhibit to the st jude medical inc current report on form dated july kexhibittableitem no fourth supplemental indenture dated of april between st jude medical llc successor to st jude medical inc and bank national association trustee relating to st jude medical llc senior note due and senior note due including form of note filed exhibit to the st jude medical inc current report on form dated april fifth supplemental indenture dated of september between st jude medical llc successor to st jude medical inc and bank national association trustee relating to st jude medical llc senior note due senior note due and senior note due filed exhibit to the st jude medical inc current report on form dated september sixth supplemental indenture dated of january among st jude medical inc st jude medical llc and bank national association trustee filed exhibit to the st jude medical llc current report on form dated january form of seventh supplemental indenture between st jude medical llc and bank national association trustee filed exhibit to the abbott laboratory registration statement on form dated february indenture dated september among abbott ireland financing dac issuer abbott laboratory guarantor and bank national association trustee filed exhibit to the abbott laboratory current report on form dated september first supplemental indenture dated september among abbott ireland financing dac issuer abbott laboratory guarantor bank national association trustee elavon financial service dac branch paying agent and transfer agent and elavon financial service dac registrar filed exhibit to the abbott laboratory current report on form dated september second supplemental indenture dated november among abbott ireland financing dac issuer abbott laboratory guarantor bank national association trustee and elavon financial service dac paying agent transfer agent and registrar filed exhibit to the abbott laboratory current report on form dated november form of note due included in exhibit to the abbott laboratory current report on form dated september form of note due included in exhibit to the abbott laboratory current report on form dated september form of note due included in exhibit to the abbott laboratory current report on form dated november form of note due included in exhibit to the abbott laboratory current report on form dated november officer certificate pursuant to section and of the indenture with respect to note due and note due filed exhibit to the abbott laboratory current report on form dated june kexhibittableitem no form of note due filed exhibit to the abbott laboratory current report on form filed on june included in exhibit to the abbott laboratory current report on form dated june form of note due filed exhibit to the abbott laboratory current report on form filed on june included in exhibit to the abbott laboratory current report on form dated june other debt instrument are omitted in accordance with item iii of regulation copy of such agreement will be furnished to the security and exchange commission upon request description of registrant security supplemental plan abbott laboratory extended disability plan filed an exhibit page to the abbott laboratory annual report on form abbott laboratory deferred compensation plan amended filed exhibit to the abbott laboratory annual report on form abbott laboratory supplemental plan amended and restated filed exhibit to the abbott laboratory annual report on form abbott laboratory supplemental pension plan amended and restated filed exhibit to the abbott laboratory annual report on form abbott laboratory management incentive plan amended and restated filed exhibit to the abbott laboratory annual report on form abbott laboratory performance incentive plan amended filed exhibit to the abbott laboratory annual report on form rule for the abbott laboratory performance incentive plan amended and restated filed exhibit to the abbott laboratory annual report on form abbott laboratory incentive stock program amended and restated filed exhibit to the abbott laboratory annual report on form abbott laboratory incentive stock program incorporated by reference to exhibit of abbott definitive proxy statement on schedule filed with the security and exchange commission on march abbott laboratory non employee director fee plan amended and restated filed exhibit to the abbott laboratory annual report on form form of non employee director restricted stock unit agreement under abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated december form of non employee director non qualified stock option agreement filed exhibit to the abbott laboratory current report on form dated april kexhibittableitem no form of non employee director restricted stock unit agreement filed exhibit to the abbott laboratory current report on form dated april form of non qualified stock option agreement ratably vested filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign executive officer annual performance based filed exhibit to the abbott laboratory annual report on form form of performance restricted stock unit agreement for foreign executive officer interim performance based filed exhibit to the abbott laboratory annual report on form form of restricted stock unit agreement for executive officer cliff vested filed exhibit to the abbott laboratory annual report on form form of restricted stock unit agreement for foreign executive officer cliff vested filed exhibit to the abbott laboratory annual report on form form of non employee director restricted stock unit agreement filed exhibit to the abbott laboratory annual report on form form of non employee director restricted stock unit agreement for foreign non employee director filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement for executive officer annual performance based filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement for executive officer interim performance based filed exhibit to the abbott laboratory annual report on form form of restricted stock agreement for executive officer cliff vested filed exhibit to the abbott laboratory annual report on form form of non qualified stock option agreement filed exhibit to the abbott laboratory annual report on form form of non qualified stock option agreement for executive officer filed exhibit to the abbott laboratory annual report on form form of non qualified stock option agreement for foreign employee filed exhibit to the abbott laboratory annual report on form form of non qualified stock option agreement for foreign executive officer filed exhibit to the abbott laboratory annual report on form form of non employee director non qualified stock option agreement filed exhibit to the abbott laboratory annual report on form kexhibittableitem no form of non employee director non qualified stock option agreement for foreign non employee director filed exhibit to the abbott laboratory annual report on form form of restricted stock unit agreement ratably vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock unit agreement for foreign employee ratably vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock unit agreement cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock unit agreement for foreign employee cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign employee annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign employee interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock agreement ratably vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock agreement cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock agreement annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock agreement interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non qualified stock option agreement under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non qualified stock option agreement for foreign employee under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april kexhibittableitem no form of restricted stock unit agreement for executive officer cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock unit agreement for foreign executive officer cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign executive officer annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign executive officer interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock agreement for executive officer ratably vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of restricted stock agreement for executive officer cliff vested under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock agreement for executive officer annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock agreement for executive officer interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non qualified stock option agreement for executive officer under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non qualified stock option agreement for foreign executive officer under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non employee director restricted stock unit agreement under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non employee director restricted stock unit agreement for foreign non employee director under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april kexhibittableitem no form of non employee director non qualified stock option agreement under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of non employee director non qualified stock option agreement for foreign non employee director under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory current report on form dated april form of performance restricted stock unit agreement for foreign employee annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock unit agreement for foreign employee interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock unit agreement for foreign executive officer annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock unit agreement for foreign executive officer interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement for executive officer annual performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of performance restricted stock agreement for executive officer interim performance based under the abbott laboratory incentive stock program filed exhibit to the abbott laboratory annual report on form form of agreement regarding change in control by and between abbott laboratory and it named executive officer other than mr white filed exhibit to the abbott laboratory current report on form dated november form of extension of agreement regarding change in control by and between abbott laboratory and it named executive officer other than mr white extending the agreement term to december filed exhibit to the abbott laboratory annual report on form form of time sharing agreement between abbott laboratory inc and white filed exhibit to the abbott laboratory quarterly report on form for the quarter ended june kexhibittableitem no form of time sharing agreement between abbott laboratory inc and robert ford filed exhibit to the abbott laboratory annual report on form st jude medical inc stock incentive plan amended and restated filed exhibit to st jude medical inc annual report on form for the year ended january dated february form of non qualified stock option agreement global and related notice of non qualified stock option grant for stock option granted on or after december under the st jude medical inc stock incentive plan filed exhibit to the st jude medical inc annual report on form for the year ended december dated february form of non qualified stock option agreement for non employee director and related notice of non qualified stock option grant for stock option granted on or after december under the st jude medical inc stock incentive plan filed exhibit to the st jude medical inc annual report on form for the year ended december dated february form of restricted stock unit award agreement global and related restricted stock unit award certificate for restricted stock unit granted on or after december under the st jude medical inc stock incentive plan filed exhibit to the st jude medical inc annual report on form for the year ended december dated february management saving plan amended and restated filed exhibit to the abbott laboratory annual report on form abbott overseas manager pension plan amended and restated filed exhibit to the abbott laboratory annual report on form five year credit agreement dated of november among abbott laboratory borrower various financial institution lender and jpmorgan chase bank administrative agent filed exhibit to the abbott laboratory annual report on form subsidiary of abbott laboratory consent of independent registered public accounting firm certification of chief executive officer required by rule cfr certification of chief financial officer required by rule cfr exhibit and are furnished herewith and should not be deemed to be filed under the security exchange act of certification of chief executive officer pursuant to section adopted pursuant to section of the sarbanes oxley act of certification of chief financial officer pursuant to section adopted pursuant to section of the sarbanes oxley act of kexhibittableitem no the following financial statement and note from the abbott laboratory annual report on form for the year ended december filed on february formatted in inline xbrl consolidated statement of earnings ii consolidated statement of comprehensive income iii consolidated statement of cash flow iv consolidated balance sheet consolidated statement of shareholder investment and vi the note to the consolidated financial statement cover page interactive data file the cover page xbrl tag are embedded in the inline xbrl document and included in exhibit incorporated herein by reference commission file number denotes management contract or compensatory plan or arrangement required to be filed an exhibit hereto incorporated herein by reference commission file number abbott will furnish copy of any of the above exhibit to shareholder upon written request to the secretary abbott laboratory abbott park road abbott park illinois financial statement schedule filed page item form summarynone signaturespursuant to the requirement of section or of the security exchange act of abbott laboratory ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized abbott laboratory by robert ford robert ford chairman of the board and chief executive officer date february pursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of abbott laboratory on february in the capacity indicated below robert ford robert funck jr robert ford robert funck jr chairman of the board and chief executive officer and director of abbott laboratory principal executive officer executive vice president financeand chief financial officer principal financial officer philip boudreau philip boudreau vice president finance and controller principal accounting officer robert alpern roxanne austinrobert alpern roxanne austindirector of abbott laboratory director of abbott laboratory sally blount paola gonzalezsally blount ph paola gonzalezdirector of abbott laboratory director of abbott laboratory michelle kumbier darren mcdewmichelle kumbierdirector of abbott laboratory darren mcdewdirector of abbott laboratory nancy mckinstry william osbornnancy mckinstry william osborndirector of abbott laboratory director of abbott laboratory michael roman daniel starksmichael roman daniel starksdirector of abbott laboratory director of abbott laboratory john stratton glenn tiltonjohn stratton glenn tiltondirector of abbott laboratory director of abbott laboratory abbott laboratory and subsidiariesschedule ii valuation and qualifying accountsfor the year ended december and in million of dollar amount balance provision charged off allowance for doubtful at beginning charge and other balance ataccounts and product return of year to income deduction end of report of independent registered public accounting firmto the shareholder and board of director of abbott laboratoriesopinion on the financial statement schedulewe have audited the consolidated financial statement of abbott laboratory and subsidiary the company of december and for each of the three year in the period ended december and have issued our report thereon dated february included elsewhere in this annual report on form our audit of the consolidated financial statement included the financial statement schedule listed in item of this annual report on form the schedule this schedule is the responsibility of the company management our responsibility is to express an opinion on the company schedule based on our audit in our opinion the schedule present fairly in all material respect the information set forth therein when considered in conjunction with the consolidated financial statement ernst young llpchicago illinoisfebruary copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next